

# Charles B Nemeroff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1373353/publications.pdf>

Version: 2024-02-01

743  
papers

71,590  
citations

518

131  
h-index

1040

242  
g-index

796  
all docs

796  
docs citations

796  
times ranked

46255  
citing authors

#	ARTICLE	IF	CITATIONS
1	Recognizing the importance of childhood maltreatment as a critical factor in psychiatric diagnoses, treatment, research, prevention, and education. <i>Molecular Psychiatry</i> , 2022, 27, 1331-1338.	4.1	100
2	Back to the Future: Esmethadone, the (Maybe) Nonopioid Opioid, and Depression. <i>American Journal of Psychiatry</i> , 2022, 179, 83-84.	4.0	6
3	Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. <i>American Journal of Psychiatry</i> , 2022, 179, 98-109.	4.0	42
4	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. <i>Molecular Psychiatry</i> , 2022, 27, 1286-1299.	4.1	68
5	Going beyond risk factor: Childhood maltreatment and associated modifiable targets to improve life-long outcomes in mood disorders. <i>Pharmacology Biochemistry and Behavior</i> , 2022, 215, 173361.	1.3	12
6	Development and psychometric properties of the sexual and gender minority adverse childhood experiences (SGM-ACEs): Effect on sexual and gender minority adult mental health. <i>Child Abuse and Neglect</i> , 2022, 127, 105570.	1.3	19
7	Laboratory models of post-traumatic stress disorder: The elusive bridge to translation. <i>Neuron</i> , 2022, 110, 1754-1776.	3.8	33
8	A meta-analysis of conditioned fear generalization in anxiety-related disorders. <i>Neuropsychopharmacology</i> , 2022, 47, 1652-1661.	2.8	22
9	Prior trauma-related experiences predict the development of posttraumatic stress disorder after a new traumatic event. <i>Depression and Anxiety</i> , 2021, 38, 40-47.	2.0	16
10	Transcription Factor Motifs Associated with Anterior Insula Gene Expression Underlying Mood Disorder Phenotypes. <i>Molecular Neurobiology</i> , 2021, 58, 1978-1989.	1.9	4
11	Psychedelics and Psychedelic-Assisted Psychotherapy. <i>Focus (American Psychiatric Publishing)</i> , 2021, 19, 95-115.	0.4	6
12	Precision Psychiatry: Biomarker-Guided Tailored Therapy for Effective Treatment and Prevention in Major Depression. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1305, 535-563.	0.8	6
13	Single-cell molecular profiling of all three components of the HPA axis reveals adrenal ABCB1 as a regulator of stress adaptation. <i>Science Advances</i> , 2021, 7, .	4.7	42
14	Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 172-179.	0.7	5
15	Combined effects of genotype and childhood adversity shape variability of DNA methylation across age. <i>Translational Psychiatry</i> , 2021, 11, 88.	2.4	27
16	The Trifecta of Misery and Disease Vulnerability: Poverty, Childhood Maltreatment, and Inflammation. <i>American Journal of Psychiatry</i> , 2021, 178, 282-284.	4.0	3
17	Integration of peripheral transcriptomics, genomics, and interactomics following trauma identifies causal genes for symptoms of post-traumatic stress and major depression. <i>Molecular Psychiatry</i> , 2021, 26, 3077-3092.	4.1	15
18	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , 2021, 178, 383-399.	4.0	270

#	ARTICLE	IF	CITATIONS
19	Neuroimaging Biomarkers in Schizophrenia. <i>American Journal of Psychiatry</i> , 2021, 178, 509-521.	4.0	117
20	Special issue editorial: Personalized medicine in psychiatry in the COVID-19 era: Fighting the impact of the pandemic on mental health. <i>Personalized Medicine in Psychiatry</i> , 2021, 27-28, 100077.	0.1	0
21	A Clinical Rationale for Assessing the Impact of Childhood Sexual Abuse on Adjunctive Subcutaneous Esketamine for Treatment-Resistant Depression. <i>Frontiers in Psychiatry</i> , 2021, 12, 608499.	1.3	1
22	Validity and severity thresholds for the depression subscale of the Affective Self Rating Scale: an equipercentile equating study using classical test theory. <i>Journal of Affective Disorders</i> , 2021, 296, 541-548.	2.0	2
23	Sex Differences in Peritraumatic Inflammatory Cytokines and Steroid Hormones Contribute to Prospective Risk for Nonremitting Posttraumatic Stress Disorder. <i>Chronic Stress</i> , 2021, 5, 247054702110322.	1.7	12
24	Childhood maltreatment, prefrontal-paralimbic gray matter volume, and substance use in young adults and interactions with risk for bipolar disorder. <i>Scientific Reports</i> , 2021, 11, 123.	1.6	12
25	Can personalized medicine mitigate confirmation bias in mental health?. <i>Revista Brasileira De Psiquiatria</i> , 2021, , .	0.9	0
26	The relationship between substance use, prior trauma history, and risk of developing post-traumatic stress disorder in the immediate aftermath of civilian trauma. <i>Journal of Psychiatric Research</i> , 2021, 144, 345-352.	1.5	2
27	Special Report: Management of Major Depression—Yesterday, Today, and Tomorrow. <i>Psychiatric News</i> , 2021, 56, .	0.0	0
28	Childhood adversity modulation of central autonomic network components during cognitive regulation of emotion in major depressive disorder and borderline personality disorder.. <i>Psychiatry Research - Neuroimaging</i> , 2021, 318, 111394.	0.9	3
29	Amyloid and Tau in Alzheimer's Disease: Biomarkers or Molecular Targets for Therapy? Are We Shooting the Messenger?. <i>American Journal of Psychiatry</i> , 2021, 178, 1014-1025.	4.0	11
30	The Devastating Clinical Consequences of Child Abuse and Neglect: Increased Disease Vulnerability and Poor Treatment Response in Mood Disorders. <i>American Journal of Psychiatry</i> , 2020, 177, 20-36.	4.0	265
31	Association of Prospective Risk for Chronic PTSD Symptoms With Low TNF $\alpha$ and IFN $\gamma$ Concentrations in the Immediate Aftermath of Trauma Exposure. <i>American Journal of Psychiatry</i> , 2020, 177, 58-65.	4.0	46
32	Investigation of MORC1 DNA methylation as biomarker of early life stress and depressive symptoms. <i>Journal of Psychiatric Research</i> , 2020, 120, 154-162.	1.5	9
33	Somatic symptoms in treatment-naïve Hispanic and non-Hispanic patients with major depression. <i>Depression and Anxiety</i> , 2020, 37, 156-165.	2.0	21
34	Candidate Biomarkers of Suicide Crisis Syndrome: What to Test Next? A Concept Paper. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 192-205.	1.0	43
35	Further Study Warranted to Evaluate TNF $\alpha$ and IFN $\gamma$ as Biomarkers for PTSD Risk: Response to Na. <i>American Journal of Psychiatry</i> , 2020, 177, 93-94.	4.0	2
36	White matter fiber density abnormalities in cognitively normal adults at risk for late-onset Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2020, 122, 79-87.	1.5	15

#	ARTICLE	IF	CITATIONS
37	Social media recruitment for mental health research: A systematic review. <i>Comprehensive Psychiatry</i> , 2020, 103, 152197.	1.5	41
38	A health care workers mental health crisis line in the age of COVID-19. <i>Depression and Anxiety</i> , 2020, 37, 822-826.	2.0	49
39	Diurnal variation of heart rate variability as a physiological index of mood and emotion regulation processes in Major Depression and Borderline Personality Disorder. <i>Personalized Medicine in Psychiatry</i> , 2020, 23-24, 100065.	0.1	2
40	Identification of a Signaling Mechanism by Which the Microbiome Regulates Th17 Cell-Mediated Depressive-Like Behaviors in Mice. <i>American Journal of Psychiatry</i> , 2020, 177, 974-990.	4.0	58
41	Insular functional alterations in emotional processing of schizophrenia patients revealed by Multivariate Pattern Analysis fMRI. <i>Journal of Psychiatric Research</i> , 2020, 130, 128-136.	1.5	5
42	The State of Our Understanding of the Pathophysiology and Optimal Treatment of Depression: Glass Half Full or Half Empty?. <i>American Journal of Psychiatry</i> , 2020, 177, 671-685.	4.0	84
43	The Moderating Effect of Resilience on the Relationship between Adverse Childhood Experiences (ACEs) and Quality of Physical and Mental Health among Adult Sexual and Gender Minorities. <i>Behavioral Medicine</i> , 2020, 46, 366-374.	1.0	18
44	Screening for Adverse Childhood Experiences. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1789.	3.8	5
45	Implementation of Advanced Methods for Reproductive Pharmacovigilance in Autism: A Meta-Analysis of the Effects of Prenatal Antidepressant Exposure. <i>American Journal of Psychiatry</i> , 2020, 177, 506-517.	4.0	14
46	Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study. <i>Journal of Psychiatric Research</i> , 2020, 128, 43-51.	1.5	15
47	Pharmacological Treatment of Anxiety Disorders: The Role of the HPA Axis. <i>Frontiers in Psychiatry</i> , 2020, 11, 443.	1.3	73
48	Hormonal Treatments for Major Depressive Disorder: State of the Art. <i>American Journal of Psychiatry</i> , 2020, 177, 686-705.	4.0	119
49	Neuro-transcriptomic signatures for mood disorder morbidity and suicide mortality. <i>Journal of Psychiatric Research</i> , 2020, 127, 62-74.	1.5	22
50	Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOt) metric for a personalised psychiatry. <i>BMC Medicine</i> , 2020, 18, 170.	2.3	21
51	The Bidirectional Relationship of Depression and Inflammation: Double Trouble. <i>Neuron</i> , 2020, 107, 234-256.	3.8	831
52	A validated predictive algorithm of post-traumatic stress course following emergency department admission after a traumatic stressor. <i>Nature Medicine</i> , 2020, 26, 1084-1088.	15.2	90
53	Psychedelics and Psychedelic-Assisted Psychotherapy. <i>American Journal of Psychiatry</i> , 2020, 177, 391-410.	4.0	309
54	Disrupted functional connectivity of the locus coeruleus in healthy adults with parental history of Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2020, 123, 81-88.	1.5	16

#	ARTICLE	IF	CITATIONS
55	Neuroendocrine Alterations in Major Depressive Disorder. , 2020, , 63-74.		1
56	Early Life Stress and Substance Use Disorders: Underlying Neurobiology and Pathways to Adverse Outcomes. Adversity and Resilience Science, 2020, 1, 29-47.	1.2	20
57	Personalized Clinical Approaches to Anxiety Disorders. Advances in Experimental Medicine and Biology, 2020, 1191, 489-521.	0.8	9
58	Double Trouble: Treatment Considerations for Patients with Comorbid PTSD and Depression. Current Treatment Options in Psychiatry, 2020, 7, 258-274.	0.7	12
59	Pharmacogenomic testing and antidepressant response: problems and promises. Revista Brasileira De Psiquiatria, 2020, 42, 116-117.	0.9	9
60	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. Archives of Clinical Neuropsychology, 2019, 34, 539-547.	0.3	4
61	Psychoneuroendocrinology of Resilience: An Overview. , 2019, , 461-469.		0
62	Convergent neurobiological predictors of mood and anxiety symptoms and treatment response. Expert Review of Neurotherapeutics, 2019, 19, 587-597.	1.4	11
63	Differences in adverse childhood experiences (ACEs) and quality of physical and mental health between transgender and cisgender sexual minorities. Journal of Psychiatric Research, 2019, 119, 1-6.	1.5	95
64	Recall accuracy for the symptoms of a major depressive episode among clinical trial participants. Journal of Psychiatric Research, 2019, 116, 178-184.	1.5	14
65	Executive functioning in cognitively normal middle-aged offspring of late-onset Alzheimer's disease patients. Journal of Psychiatric Research, 2019, 112, 23-29.	1.5	13
66	Benefits of Sequentially Adding Cognitive-Behavioral Therapy or Antidepressant Medication for Adults With Nonremitting Depression. American Journal of Psychiatry, 2019, 176, 275-286.	4.0	43
67	The Long-Lasting Neurobiological Scars of Early-Life Stress: Implications for the Neurobiology of Depression. , 2019, , 111-121.		8
68	Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder. Psychological Medicine, 2019, 49, 1869-1878.	2.7	13
69	EEG Biomarkers for Treatment Response Prediction in Major Depressive Illness. American Journal of Psychiatry, 2019, 176, 82-82.	4.0	4
70	Brain Structural and Amyloid Correlates of Recovery From Semantic Interference in Cognitively Normal Individuals With or Without Family History of Late-Onset Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2019, 31, 25-36.	0.9	11
71	Electroencephalographic Biomarkers for Treatment Response Prediction in Major Depressive Illness: A Meta-Analysis. American Journal of Psychiatry, 2019, 176, 44-56.	4.0	122
72	Biomarker-Guided Tailored Therapy. Advances in Experimental Medicine and Biology, 2019, 1192, 199-224.	0.8	12

#	ARTICLE	IF	CITATIONS
73	Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. <i>American Journal of Psychiatry</i> , 2018, 175, 873-886.	4.0	119
74	Interoception and Mental Health: A Roadmap. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 501-513.	1.1	524
75	Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder. <i>Journal of Affective Disorders</i> , 2018, 229, 111-119.	2.0	9
76	Precision Psychiatry: Personalized Clinical Approach to Depression. , 2018, , 245-261.		0
77	Ketamine: Quo Vadis?. <i>American Journal of Psychiatry</i> , 2018, 175, 297-299.	4.0	15
78	Personalized medicine: Prediction of disease vulnerability in mood disorders. <i>Neuroscience Letters</i> , 2018, 669, 10-13.	1.0	29
79	Reduced left ventricular dimension and function following early life stress: A thrifty phenotype hypothesis engendering risk for mood and anxiety disorders. <i>Neurobiology of Stress</i> , 2018, 8, 202-210.	1.9	9
80	Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. <i>American Journal of Psychiatry</i> , 2018, 175, 251-261.	4.0	39
81	The Role of Oxytocin in Early Life Adversity and Later Psychopathology: a Review of Preclinical and Clinical Studies. <i>Current Treatment Options in Psychiatry</i> , 2018, 5, 401-415.	0.7	11
82	DNA methylation levels are associated with CRF1 receptor antagonist treatment outcome in women with post-traumatic stress disorder. <i>Clinical Epigenetics</i> , 2018, 10, 136.	1.8	36
83	Measurement invariance of the Childhood Trauma Questionnaire by gender, poverty level, and HIV status. <i>Personalized Medicine in Psychiatry</i> , 2018, 11-12, 16-22.	0.1	6
84	Cortical thickness, brain metabolic activity, and in vivo amyloid deposition in asymptomatic, middle-aged offspring of patients with late-onset Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2018, 107, 11-18.	1.5	16
85	Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse. <i>Depression and Anxiety</i> , 2018, 35, 992-1000.	2.0	23
86	More Research Needed on the Association Between Genotype and Antidepressant Response: Response to Fabbri et al.. <i>American Journal of Psychiatry</i> , 2018, 175, 576-577.	4.0	3
87	The Search for Treatments for Veterans With Major Depression. <i>JAMA Psychiatry</i> , 2018, 75, 877.	6.0	5
88	Early Life Stress Associated With Increased Striatal N-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass, and Behavioral Correlates. <i>Chronic Stress</i> , 2018, 2, 247054701876845.	1.7	6
89	Drug Repositioning in Glioblastoma: A Pathway Perspective. <i>Frontiers in Pharmacology</i> , 2018, 9, 218.	1.6	78
90	Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. <i>Neuron</i> , 2018, 99, 914-924.e3.	3.8	153

#	ARTICLE	IF	CITATIONS
91	Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence.. Journal of Consulting and Clinical Psychology, 2018, 86, 189-199.	1.6	15
92	Neurobiological Pathways Involved in Fear, Stress, and PTSD. , 2018, , .		4
93	Animal Models for Post-Traumatic Stress Disorder. , 2018, , .		0
94	The structure of personality disorders within a depressed sample: Implications for personalizing treatment. Personalized Medicine in Psychiatry, 2017, 1-2, 59-64.	0.1	3
95	A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry, 2017, 74, 399.	6.0	433
96	Early Life Stress, Mood, and Anxiety Disorders. Chronic Stress, 2017, 1, 247054701769446.	1.7	90
97	Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study. American Journal of Psychiatry, 2017, 174, 546-556.	4.0	107
98	Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder. American Journal of Psychiatry, 2017, 174, 533-545.	4.0	268
99	Adult glucocorticoid receptor mRNA expression volatility in response to an acute stressor and juvenile CSF corticotropin-releasing factor: A pilot neurodevelopmental study. Neuroscience Letters, 2017, 647, 20-25.	1.0	2
100	Putative biological predictors of treatment response in bipolar disorders. Personalized Medicine in Psychiatry, 2017, 1-2, 39-58.	0.1	1
101	Amygdala Reactivity and Anterior Cingulate Habituation Predict Posttraumatic Stress Disorder Symptom Maintenance After Acute Civilian Trauma. Biological Psychiatry, 2017, 81, 1023-1029.	0.7	145
102	Suicidal ideation and behavior in institutions of higher learning: A latent class analysis. Journal of Psychiatric Research, 2017, 95, 253-259.	1.5	26
103	Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Biological Psychiatry, 2017, 82, 866-874.	0.7	74
104	[P1â€“324]: SEMANTIC INTERFERENCE DEFICITS AND THEIR RELATIONSHIP WITH SLEEPâ€“WAKE PHENOTYPES IN ASYMPTOMATIC OFFSPRING OF LATEâ€“ONSET ALZHEIMER'S AND ACUTE DISEASE PATIENTS. Alzheimer's and Dementia, 2017, 13, P379.	0.4	0
105	Failure to Recover from Proactive Semantic Interference and Abnormal Limbic Connectivity in Asymptomatic, Middle-Aged Offspring of Patients with Late-Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 1183-1193.	1.2	31
106	Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity. PLoS Biology, 2017, 15, e2002690.	2.6	28
107	Response to Zhang and Ho: Addressing Ketamineâ€™s Use in Depression. American Journal of Psychiatry, 2016, 173, 431-432.	4.0	0
108	Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests. Psychoneuroendocrinology, 2016, 69, 161-171.	1.3	33

#	ARTICLE	IF	CITATIONS
109	Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11955-11960.	3.3	50
110	WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?. <i>Depression and Anxiety</i> , 2016, 33, 685-688.	2.0	26
111	Genome-wide DNA methylation levels and altered cortisol stress reactivity following childhood trauma in humans. <i>Nature Communications</i> , 2016, 7, 10967.	5.8	175
112	More Time for Science and Less Time for Administration?. <i>Neuropsychopharmacology</i> , 2016, 41, 2625-2626.	2.8	0
113	EFFICACY AND LONG-TERM CLINICAL OUTCOME OF COMORBID POSTTRAUMATIC STRESS DISORDER AND MAJOR DEPRESSIVE DISORDER AFTER ELECTROCONVULSIVE THERAPY. <i>Depression and Anxiety</i> , 2016, 33, 640-647.	2.0	39
114	Triiodothyronine accelerates and enhances the antipsychotic effect of risperidone in acute schizophrenia. <i>Journal of Psychiatric Research</i> , 2016, 73, 9-16.	1.5	4
115	The Links Between Stress and Depression: Psychoneuroendocrinological, Genetic, and Environmental Interactions. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2016, 28, 77-88.	0.9	201
116	Paradise Lost: The Neurobiological and Clinical Consequences of Child Abuse and Neglect. <i>Neuron</i> , 2016, 89, 892-909.	3.8	547
117	Childhood trauma and METH abuse among men who have sex with men: Implications for intervention. <i>Journal of Psychiatric Research</i> , 2016, 72, 1-5.	1.5	35
118	State-of-the-Art Prevention and Treatment of PTSD: Pharmacotherapy, Psychotherapy, and Nonpharmacological Somatic Therapies. <i>Psychiatric Annals</i> , 2016, 46, 533-549.	0.1	4
119	Understanding Posttraumatic Stress Disorder: From Diagnosis and Neurobiology to Treatment. <i>Psychiatric Annals</i> , 2016, 46, 494-496.	0.1	1
120	The interface of depression and cardiovascular disease: therapeutic implications. <i>Annals of the New York Academy of Sciences</i> , 2015, 1345, 25-35.	1.8	102
121	This issue: Inflammation and Psychiatric Disorders. <i>Psychiatric Annals</i> , 2015, 45, 222-224.	0.1	2
122	Lifetime stress accelerates epigenetic aging in an urban, African American cohort: relevance of glucocorticoid signaling. <i>Genome Biology</i> , 2015, 16, 266.	3.8	340
123	Brain activation induced by psychological stress in patients with schizophrenia. <i>Schizophrenia Research</i> , 2015, 168, 313-321.	1.1	14
124	From Semantic to Social Deficits: Dysfunction of the Nondominant Posterior Perisylvian Area in Schizophrenia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2015, 27, 254-261.	0.9	6
125	Metabolic syndrome, major depression, generalized anxiety disorder, and ten-year all-cause and cardiovascular mortality in middle aged and elderly patients. <i>International Journal of Cardiology</i> , 2015, 190, 360-366.	0.8	56
126	The Preeminence of Early Life Trauma as a Risk Factor for Worsened Long-Term Health Outcomes in Women. <i>Current Psychiatry Reports</i> , 2015, 17, 90.	2.1	19



#	ARTICLE	IF	CITATIONS
127	Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. <i>American Journal of Psychiatry</i> , 2015, 172, 950-966.	4.0	489
128	Personalized Medicine and Mood Disorders. <i>Psychiatric Clinics of North America</i> , 2015, 38, 395-403.	0.7	30
129	Striatal dopamine receptor plasticity in neurotensin deficient mice. <i>Behavioural Brain Research</i> , 2015, 280, 160-171.	1.2	8
130	Treatment of affective disorders in cardiac disease. <i>Dialogues in Clinical Neuroscience</i> , 2015, 17, 127-140.	1.8	18
131	Early life stress and macaque amygdala hypertrophy: preliminary evidence for a role for the serotonin transporter gene. <i>Frontiers in Behavioral Neuroscience</i> , 2014, 8, 342.	1.0	38
132	Marked Reduction in Serotonergic Activity in a Sexually Aggressive Adolescent Male. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2014, 26, 262-270.	0.9	0
133	PSYCHOPHARMACOLOGY AND THE FUTURE OF PERSONALIZED TREATMENT. <i>Depression and Anxiety</i> , 2014, 31, 906-908.	2.0	4
134	Ellen Stover. <i>Neuropsychopharmacology</i> , 2014, 39, 3132-3132.	2.8	0
135	Impulsive Choice and Psychological Pain in Acutely Suicidal Depressed Patients. <i>Psychosomatic Medicine</i> , 2014, 76, 445-451.	1.3	70
136	Effects of Duloxetine on Norepinephrine and Serotonin Transporter Activity in Healthy Subjects. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 9-16.	0.7	15
137	Toward an Understanding of Decision Making in Severe Mental Illness. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2014, 26, 196-213.	0.9	73
138	Depression as a Risk Factor for Cancer: From Pathophysiological Advances to Treatment Implications. <i>Annual Review of Medicine</i> , 2014, 65, 203-221.	5.0	88
139	Interaction of Stress, Corticotropin-Releasing Factor, Arginine Vasopressin and Behaviour. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 18, 67-80.	0.8	40
140	Underestimation of substance abuse in psychiatric patients by conventional hospital screening. <i>Journal of Psychiatric Research</i> , 2014, 59, 206-212.	1.5	9
141	Emerging antidepressants to treat major depressive disorder. <i>Asian Journal of Psychiatry</i> , 2014, 12, 7-16.	0.9	38
142	Variation in the oxytocin receptor gene is associated with increased risk for anxiety, stress and depression in individuals with a history of exposure to early life stress. <i>Journal of Psychiatric Research</i> , 2014, 59, 93-100.	1.5	78
143	Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 240.	0.7	41
144	The Preeminent Role of Childhood Abuse and Neglect in Vulnerability to Major Psychiatric Disorders: Toward Elucidating the Underlying Neurobiological Mechanisms. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2014, 53, 395-397.	0.3	48

#	ARTICLE	IF	CITATIONS
145	Pattern of brain activation during social cognitive tasks is related to social competence in siblings discordant for schizophrenia. <i>Journal of Psychiatric Research</i> , 2014, 56, 120-129.	1.5	13
146	Early Life Trauma and Suicide. , 2014, , 187-205.		9
147	Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 62-68.	1.1	31
148	Personalized medicine in psychiatry: problems and promises. <i>BMC Medicine</i> , 2013, 11, 132.	2.3	192
149	Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial. <i>Trials</i> , 2013, 14, 224.	0.7	34
150	Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. <i>Nature Neuroscience</i> , 2013, 16, 33-41.	7.1	1,216
151	The Ups and Downs of Bipolar Disorder Research. <i>Biological Psychiatry</i> , 2013, 73, 597-599.	0.7	3
152	Endocrine associations with health-related quality of life in coronary artery disease patients. <i>International Journal of Cardiology</i> , 2013, 164, 246-248.	0.8	5
153	Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala. <i>Psychoneuroendocrinology</i> , 2013, 38, 1349-1361.	1.3	35
154	Activation of brain areas concerned with social cognition during moral decisions is abnormal in schizophrenia patients and unaffected siblings. <i>Journal of Psychiatric Research</i> , 2013, 47, 774-782.	1.5	15
155	DSM-5: a collection of psychiatrist views on the changes, controversies, and future directions. <i>BMC Medicine</i> , 2013, 11, 202.	2.3	86
156	Decision-Making in Diabetes Mellitus Type 1. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2013, 25, 40-50.	0.9	21
157	Decreased Cortical Representation of Genital Somatosensory Field After Childhood Sexual Abuse. <i>American Journal of Psychiatry</i> , 2013, 170, 616-623.	4.0	261
158	PSYCHONEUROIMMUNOENDOCRINOLOGY: THE BIOLOGICAL BASIS OF MIND-BODY PHYSIOLOGY AND PATHOPHYSIOLOGY. <i>Depression and Anxiety</i> , 2013, 30, 285-287.	2.0	12
159	DECREASED BRAINSTEM AND PUTAMEN SERT BINDING POTENTIAL IN DEPRESSED SUICIDE ATTEMPTERS USING [ <sup>11</sup> C]-ZIENT PET IMAGING. <i>Depression and Anxiety</i> , 2013, 30, n/a-n/a.	2.0	40
160	The Pervasive and Persistent Neurobiological and Clinical Aftermath of Child Abuse and Neglect. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 999-1001.	1.1	14
161	Unipolar depression. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 239-249.	1.0	7
162	New-Onset Psychosis Associated With Dandy-Walker Variant in an Adolescent Female Patient. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2012, 24, 241-246.	0.9	18

#	ARTICLE	IF	CITATIONS
163	The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. <i>Journal of Psychiatric Research</i> , 2012, 46, 1406-1413.	1.5	185
164	APOE: A Risk Factor for Multiple Disorders. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 545-548.	0.6	6
165	Etiology of Depression: Genetic and Environmental Factors. <i>Psychiatric Clinics of North America</i> , 2012, 35, 51-71.	0.7	192
166	Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. <i>Trials</i> , 2012, 13, 106.	0.7	108
167	Microembolism infarcts lead to delayed changes in affective-like behaviors followed by spatial memory impairment. <i>Behavioural Brain Research</i> , 2012, 234, 259-266.	1.2	22
168	Cerebrospinal Fluid Substance P-Like Immunoreactivity Correlates with Aggression in Personality Disordered Subjects. <i>Biological Psychiatry</i> , 2012, 72, 238-243.	0.7	24
169	Early life stress affects cerebral glucose metabolism in adult rhesus monkeys ( <i>Macaca mulatta</i> ). <i>Developmental Cognitive Neuroscience</i> , 2012, 2, 181-193.	1.9	26
170	The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion. <i>Schizophrenia Research</i> , 2012, 136, 88-95.	1.1	11
171	Decreased activity in right-hemisphere structures involved in social cognition in siblings discordant for schizophrenia. <i>Schizophrenia Research</i> , 2012, 134, 171-179.	1.1	57
172	Psychiatric epidemiology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 167-189.	1.0	7
173	Heartache and heartbreak—the link between depression and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2012, 9, 526-539.	6.1	341
174	Chronic overexpression of corticotropin-releasing factor from the central amygdala produces HPA axis hyperactivity and behavioral anxiety associated with gene-expression changes in the hippocampus and paraventricular nucleus of the hypothalamus. <i>Psychoneuroendocrinology</i> , 2012, 37, 27-38.	1.3	111
175	The effects of child abuse and neglect on cognitive functioning in adulthood. <i>Journal of Psychiatric Research</i> , 2012, 46, 500-506.	1.5	272
176	Current treatment options for insomnia. <i>Drugs of Today</i> , 2012, 48, 415.	0.7	9
177	Metabolic syndrome and neurometabolic asymmetry of hippocampus in adult bonnet monkeys. <i>Physiology and Behavior</i> , 2011, 103, 535-539.	1.0	4
178	In the Aftermath of Tragedy: Medical and Psychiatric Consequences. <i>Academic Psychiatry</i> , 2011, 35, 4-7.	0.4	3
179	Innovative Approach to Research Training: Research Colloquium for Junior Investigators. <i>Academic Psychiatry</i> , 2011, 35, 11-14.	0.4	9
180	Depression, Antidepressants, and Neurogenesis: A Critical Reappraisal. <i>Neuropsychopharmacology</i> , 2011, 36, 2589-2602.	2.8	255

#	ARTICLE	IF	CITATIONS
181	Persistent anxiolytic effects after chronic administration of the CRF1 receptor antagonist R121919 in rats. <i>Neuropharmacology</i> , 2011, 60, 1135-1141.	2.0	16
182	The effects of sertraline on psychopathic traits. <i>International Clinical Psychopharmacology</i> , 2011, 26, 329-337.	0.9	20
183	Neurobiology and Genetics of Generalized Anxiety Disorder. <i>Psychiatric Annals</i> , 2011, 41, 113-123.	0.1	13
184	Predictors of neonatal hypothalamic-pituitary-adrenal axis activity at delivery. <i>Clinical Endocrinology</i> , 2011, 75, 90-95.	1.2	30
185	Tolerability of the dexamethasone-corticotropin releasing hormone test in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 24-28.	1.5	5
186	Early-life stress, corticotropin-releasing factor, and serotonin transporter gene: A pilot study. <i>Psychoneuroendocrinology</i> , 2011, 36, 289-293.	1.3	37
187	The relationship of depression and diabetes: Pathophysiological and treatment implications. <i>Psychoneuroendocrinology</i> , 2011, 36, 1276-1286.	1.3	168
188	Several stressors fail to reduce adult hippocampal neurogenesis. <i>Psychoneuroendocrinology</i> , 2011, 36, 1520-1529.	1.3	46
189	International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. <i>Trials</i> , 2011, 12, 4.	0.7	163
190	Lithium, but Not Fluoxetine or the Corticotropin-Releasing Factor Receptor 1 Receptor Antagonist R121919, Increases Cell Proliferation in the Adult Dentate Gyrus. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 180-186.	1.3	74
191	The Role of Corticotropin-Releasing Hormone in the Pathophysiology of Depression: Therapeutic Implications. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 609-617.	1.0	62
192	Post-traumatic stress disorder: the neurobiological impact of psychological trauma. <i>Dialogues in Clinical Neuroscience</i> , 2011, 13, 263-278.	1.8	457
193	Polymorphisms in <i>CRHR1</i> and the serotonin transporter loci: Gene-Environment interactions on depressive symptoms. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 812-824.	1.1	83
194	Impact of the HTR3A gene with early life trauma on emotional brain networks and depressed mood. <i>Depression and Anxiety</i> , 2010, 27, 752-759.	2.0	69
195	Neurobiological and psychiatric consequences of child abuse and neglect. <i>Developmental Psychobiology</i> , 2010, 52, 671-690.	0.9	504
196	Changes in the Vascular Area Fraction of the Hippocampus and Amygdala are Induced by Prenatal Dexamethasone and/or Adult Stress. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1100-1104.	2.4	20
197	Asymmetrical Contribution of Brain Structures to Treatment-Resistant Depression As Illustrated by Effects of Right Subgenual Cingulum Stimulation. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2010, 22, 265-277.	0.9	46
198	Association of Polymorphisms in Genes Regulating the Corticotropin-Releasing Factor System With Antidepressant Treatment Response. <i>Archives of General Psychiatry</i> , 2010, 67, 369.	13.8	105

#	ARTICLE	IF	CITATIONS
199	A Novel Transgenic Mouse for Gene-Targeting Within Cells That Express Corticotropin-Releasing Factor. <i>Biological Psychiatry</i> , 2010, 67, 1212-1216.	0.7	41
200	Early Life Stress Combined with Serotonin 3A Receptor and Brain-Derived Neurotrophic Factor Valine 66 to Methionine Genotypes Impacts Emotional Brain and Arousal Correlates of Risk for Depression. <i>Biological Psychiatry</i> , 2010, 68, 818-824.	0.7	85
201	Early Life Programming and Neurodevelopmental Disorders. <i>Biological Psychiatry</i> , 2010, 68, 314-319.	0.7	791
202	The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology. <i>Clinics in Laboratory Medicine</i> , 2010, 30, 865-891.	0.7	81
203	Stress and the Impact of Personalized Medicine. , 2010, , 73-92.		3
204	Inflammation and Mood Disorders: Proinflammatory Cytokines and the Pathogenesis of Depression. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2010, 9, 212-220.	1.1	16
205	The Physiological Effect of Mental Processes on Major Body Systems. <i>Psychiatric Annals</i> , 2010, 40, 367-380.	0.1	4
206	Neuroendocrinology of Affective Disorders. , 2009, , 355-366.		1
207	The Role of Serotonin in the Pathophysiology of Depression: As Important As Ever. <i>Clinical Chemistry</i> , 2009, 55, 1578-1579.	1.5	56
208	The Neurobiological Toll of Child Abuse and Neglect. <i>Trauma, Violence, and Abuse</i> , 2009, 10, 389-410.	3.9	181
209	A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. <i>Journal of Psychiatric Research</i> , 2009, 43, 205-214.	1.5	97
210	Effects of a cognitive stress challenge on myocardial perfusion and plasma cortisol in coronary heart disease patients with depression. <i>Stress and Health</i> , 2009, 25, 267-278.	1.4	13
211	Cardiac Arrest and Cardiopulmonary Resuscitation Dysregulates the Hypothalamic-Pituitary-Adrenal Axis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1673-1682.	2.4	23
212	Emerging targets for antidepressant therapies. <i>Current Opinion in Chemical Biology</i> , 2009, 13, 291-302.	2.8	69
213	Synthesis, Radiosynthesis, and Biological Evaluation of Carbon-11 and Fluorine-18 Labeled Reboxetine Analogues: Potential Positron Emission Tomography Radioligands for in Vivo Imaging of the Norepinephrine Transporter. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 62-73.	2.9	30
214	Exploratory structural equation modeling of resting-state fMRI: Applicability of group models to individual subjects. <i>NeuroImage</i> , 2009, 45, 778-787.	2.1	58
215	The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology. <i>Psychiatric Clinics of North America</i> , 2009, 32, 549-575.	0.7	326
216	Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. <i>International Clinical Psychopharmacology</i> , 2009, 24, 61-86.	0.9	12

#	ARTICLE	IF	CITATIONS
217	Effect of childhood trauma on adult depression and neuroendocrine function: sex-specific moderation by CRH receptor 1 gene. <i>Frontiers in Behavioral Neuroscience</i> , 2009, 3, 41.	1.0	206
218	The Medical Consequences of Child Abuse and Neglect. <i>Psychiatric Annals</i> , 2009, 39, 1004-1009.	0.1	5
219	Brain-Body Interactions: The Physiological Impact of Mental Processes – The Neurobiology of the Stress Response. <i>Psychiatric Annals</i> , 2009, 39, 975-984.	0.1	9
220	10.5 The Role of Dopamine in the Pathophysiology and Treatment of Major Depressive Disorder. , 2009, , 572-589.		0
221	Novel targets for antidepressant therapies. <i>Current Psychiatry Reports</i> , 2008, 10, 465-473.	2.1	30
222	Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University. <i>Depression and Anxiety</i> , 2008, 25, 482-488.	2.0	565
223	Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 783-793.	1.4	17
224	Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. <i>Journal of Psychiatric Research</i> , 2008, 42, 1076-1085.	1.5	41
225	Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats. <i>Psychoneuroendocrinology</i> , 2008, 33, 178-187.	1.3	19
226	The link between childhood trauma and depression: Insights from HPA axis studies in humans. <i>Psychoneuroendocrinology</i> , 2008, 33, 693-710.	1.3	1,373
227	Behavioral effects of the CRF1 receptor antagonist R121919 in rats selectively bred for high and low activity in the swim test. <i>Psychoneuroendocrinology</i> , 2008, 33, 1093-1101.	1.3	14
228	Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs. <i>Biological Psychiatry</i> , 2008, 63, 424-434.	0.7	156
229	The Dexamethasone/Corticotropin-Releasing Factor Test in Men with Major Depression: Role of Childhood Trauma. <i>Biological Psychiatry</i> , 2008, 63, 398-405.	0.7	313
230	The Curiously Strong Relationship Between Cardiovascular Disease and Depression in the Elderly. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 857-860.	0.6	14
231	Understanding the Pathophysiology of Postpartum Depression: Implications for the Development of Novel Treatments. <i>Neuron</i> , 2008, 59, 185-186.	3.8	31
232	Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. <i>Psychiatry Research</i> , 2008, 157, 123-129.	1.7	14
233	Influence of Child Abuse on Adult Depression. <i>Archives of General Psychiatry</i> , 2008, 65, 190.	13.8	583
234	Compartmental Modeling of <sup>11</sup> C-HOMADAM Binding to the Serotonin Transporter in the Healthy Human Brain. <i>Journal of Nuclear Medicine</i> , 2008, 49, 2018-2025.	2.8	25

#	ARTICLE	IF	CITATIONS
235	Association of <i>FKBP5</i> Polymorphisms and Childhood Abuse With Risk of Posttraumatic Stress Disorder Symptoms in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 1291.	3.8	1,190
236	An Interactive Web-Based Method of Outreach to College Students at Risk for Suicide. <i>Journal of American College Health</i> , 2008, 57, 15-22.	0.8	123
237	Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine. <i>Neuropsychopharmacology</i> , 2008, 33, 3201-3212.	2.8	55
238	Platelet Thromboxane A2 Secretion in Patients With Major Depression Responsive to Electroconvulsive Therapy. <i>Psychosomatic Medicine</i> , 2008, 70, 319-327.	1.3	1
239	Fostering Foster Care Outcomes. <i>Archives of General Psychiatry</i> , 2008, 65, 623.	13.8	12
240	The Role of Corticotropin-releasing Factor in the Pathophysiology of Depression: Implications for Antidepressant Mechanisms of Action. <i>Psychiatric Annals</i> , 2008, 38, .	0.1	3
241	Stress, menopause and vulnerability for psychiatric illness. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, S11-S13.	1.4	13
242	Impact of Publicity Concerning Pediatric Suicidality Data on Physician Practice Patterns in the United States. <i>Archives of General Psychiatry</i> , 2007, 64, 466.	13.8	174
243	Atypical Antipsychotic Administration During Late Pregnancy: Placental Passage and Obstetrical Outcomes. <i>American Journal of Psychiatry</i> , 2007, 164, 1214-1220.	4.0	212
244	Antidepressant Drug-Drug Interactions: Clinical Relevance and Risk Management. <i>CNS Spectrums</i> , 2007, 12, 1-16.	0.7	22
245	Novel Pharmacologic Treatment of Stress and Addiction. , 2007, , 333-347.		1
246	The Role of Dopamine in the Pathophysiology of Depression. <i>Archives of General Psychiatry</i> , 2007, 64, 327.	13.8	991
247	Involvement of Neuropeptide Systems in Schizophrenia: Human Studies. <i>International Review of Neurobiology</i> , 2007, 78, 327-376.	0.9	27
248	Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon- $\alpha$ Therapy. <i>Neuropsychopharmacology</i> , 2007, 32, 2384-2392.	2.8	203
249	Corticotropin-Releasing Factor and the Psychobiology of Early-Life Stress. <i>Current Directions in Psychological Science</i> , 2007, 16, 85-89.	2.8	40
250	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the Acute and Continuation Phases. <i>Biological Psychiatry</i> , 2007, 62, 1371-1379.	0.7	39
251	Effects of Interferon-Alpha on Rhesus Monkeys: A Nonhuman Primate Model of Cytokine-Induced Depression. <i>Biological Psychiatry</i> , 2007, 62, 1324-1333.	0.7	189
252	Synthesis and biological evaluation of 2 $\beta$ ,3 $\beta$ -(substituted phenyl)nortropanes as potential norepinephrine transporter imaging agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3044-3047.	1.0	3

#	ARTICLE	IF	CITATIONS
253	Long-term behavioural and molecular alterations associated with maternal separation in rats. <i>European Journal of Neuroscience</i> , 2007, 25, 3091-3098.	1.2	303
254	The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. <i>European Journal of Pharmacology</i> , 2007, 571, 17-24.	1.7	33
255	A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. <i>Journal of Psychiatric Research</i> , 2007, 41, 351-359.	1.5	51
256	The burden of severe depression: A review of diagnostic challenges and treatment alternatives. <i>Journal of Psychiatric Research</i> , 2007, 41, 189-206.	1.5	258
257	The CRF1 receptor antagonist R121919 attenuates the neuroendocrine and behavioral effects of precipitated lorazepam withdrawal. <i>Psychopharmacology</i> , 2007, 192, 385-396.	1.5	25
258	Prevention of Recurrent Episodes of Depression With Venlafaxine ER in a 1-Year Maintenance Phase From the PREVENT Study. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1014-1023.	1.1	53
259	The Prevention of Recurrent Episodes of Depression With Venlafaxine for Two Years (PREVENT) Study. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1246-1256.	1.1	93
260	Corticotropin-Releasing Factor Circuitry in the Brain – Relevance for Affective Disorders and Anxiety. , 2007, , 630-634.		0
261	Prevalence and management of treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 8, 17-25.	1.1	132
262	The Diagnosis of Major Depression in Patients With Cancer: A Comparative Approach. <i>Psychosomatics</i> , 2006, 47, 376-384.	2.5	33
263	Upregulation of Striatal Dopamine-2 Receptors in Brattleboro Rats with Prepulse Inhibition Deficits. <i>Biological Psychiatry</i> , 2006, 60, 1278-1281.	0.7	24
264	Neurotensin: Role in psychiatric and neurological diseases. <i>Peptides</i> , 2006, 27, 2385-2404.	1.2	107
265	Reduced glucocorticoid receptors: consequence or cause of depression?. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 124-125.	3.1	46
266	Response to Rubin and Carroll and Van Den Eede et al.. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 387.	3.1	0
267	Persistent Auditory Hallucinations That Are Unresponsive to Antipsychotic Drugs. <i>American Journal of Psychiatry</i> , 2006, 163, 1153-1159.	4.0	14
268	Advances in the treatment of depression. <i>NeuroRx</i> , 2006, 3, 42-56.	6.0	93
269	Maternal-Infant Response to Variable Foraging Demand in Nonhuman Primates: Effects of Timing of Stressor on Cerebrospinal Fluid Corticotropin-Releasing Factor and Circulating Glucocorticoid Concentrations. <i>Annals of the New York Academy of Sciences</i> , 2006, 1071, 525-533.	1.8	37
270	Synthesis and monoamine transporter affinity of front bridged tricyclic 3Î²-(4â€²-halo or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 Td (4-2Î²-position. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4661-4663.	1.0	5



#	ARTICLE	IF	CITATIONS
271	The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression. <i>Current Psychiatry Reports</i> , 2006, 8, 452-457.	2.1	40
272	Posttraumatic stress disorder: A state-of-the-science review. <i>Journal of Psychiatric Research</i> , 2006, 40, 1-21.	1.5	587
273	Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: A switch study. <i>Journal of Psychiatric Research</i> , 2006, 40, 669-676.	1.5	29
274	Implications for the practice of psychiatry. <i>Progress in Brain Research</i> , 2006, 158, 275-293.	0.9	1
275	Genetic Analysis of the Hypothalamic Neurotensin System. <i>Neuropsychopharmacology</i> , 2006, 31, 535-543.	2.8	8
276	The Neural Correlates of Social Anxiety Disorder and Response to Pharmacotherapy. <i>Neuropsychopharmacology</i> , 2006, 31, 2243-2253.	2.8	107
277	Introducing the Point-Counterpoint Series. <i>Neuropsychopharmacology</i> , 2006, 31, 1593-1593.	2.8	1
278	Trauma Spectrum Disorders. , 2006, , 1203-1210.		3
279	Elevated Cerebrospinal Fluid Substance P Concentrations in Posttraumatic Stress Disorder and Major Depression. <i>American Journal of Psychiatry</i> , 2006, 163, 637-643.	4.0	136
280	VNS Therapy in Treatment-Resistant Depression: Clinical Evidence and Putative Neurobiological Mechanisms. <i>Neuropsychopharmacology</i> , 2006, 31, 1345-1355.	2.8	367
281	Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation. <i>Neuropsychopharmacology</i> , 2006, 31, 2505-2513.	2.8	129
282	Emerging treatments for depression. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2323-2339.	0.9	23
283	Increased Stress-Induced Inflammatory Responses in Male Patients With Major Depression and Increased Early Life Stress. <i>American Journal of Psychiatry</i> , 2006, 163, 1630-1633.	4.0	669
284	A Double-Blind, Multicenter, Parallel-Group Study of Paroxetine, Desipramine, or Placebo in Breast Cancer Patients (stages I, II, III, and IV) With Major Depression. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 288-296.	1.1	77
285	Molecular Mechanisms Regulating Behavior. , 2006, , 1175-1183.		0
286	From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone. <i>CNS Spectrums</i> , 2005, 10, 1-20.	0.7	36
287	Synchronized Maternal-Infant Elevations of Primate CSF CRF Concentrations in Response to Variable Foraging Demand. <i>CNS Spectrums</i> , 2005, 10, 530-536.	0.7	48
288	Hypercortisolemia and Depression. <i>Psychosomatic Medicine</i> , 2005, 67, S26-S28.	1.3	292

#	ARTICLE	IF	CITATIONS
289	The impact of early trauma on response to psychotherapy. <i>Clinical Neuroscience Research</i> , 2005, 4, 405-411.	0.8	20
290	Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. <i>Psychopharmacology</i> , 2005, 182, 414-419.	1.5	9
291	The electrophysiological effects of neurotensin on spontaneously active neurons in the nucleus accumbens: An in vivo study. <i>Synapse</i> , 2005, 58, 165-172.	0.6	3
292	The Efficacy of Light Therapy in the Treatment of Mood Disorders: A Review and Meta-Analysis of the Evidence. <i>American Journal of Psychiatry</i> , 2005, 162, 656-662.	4.0	769
293	Self-Reported Depressive Symptom Measures: Sensitivity to Detecting Change in a Randomized, Controlled Trial of Chronically Depressed, Nonpsychotic Outpatients. <i>Neuropsychopharmacology</i> , 2005, 30, 405-416.	2.8	115
294	Measuring the severity of depression and remission in primary care: validation of the HAMD-7 scale. <i>Cmaj</i> , 2005, 173, 1327-1334.	0.9	103
295	Effects of phenytoin on memory, cognition and brain structure in post-traumatic stress disorder: a pilot study. <i>Journal of Psychopharmacology</i> , 2005, 19, 159-165.	2.0	95
296	Functional Brain Imaging Alterations in Acne Patients Treated With Isotretinoin. <i>American Journal of Psychiatry</i> , 2005, 162, 983-991.	4.0	103
297	Comparing the Effects of Antidepressants: Consensus Guidelines for Evaluating Quantitative Reviews of Antidepressant Efficacy. <i>Neuropsychopharmacology</i> , 2005, 30, 445-460.	2.8	120
298	Genetic Analysis of the Hypothalamic Corticotropin-Releasing Factor System. <i>Endocrinology</i> , 2005, 146, 2362-2368.	1.4	10
299	Long-Term Consequences of Neonatal Rearing on Central Corticotropin-Releasing Factor Systems in Adult Male Rat Offspring. <i>Neuropsychopharmacology</i> , 2005, 30, 2192-2204.	2.8	449
300	Neurotensin-Deficient Mice Have Deficits in Prepulse Inhibition: Restoration by Clozapine but Not Haloperidol, Olanzapine, or Quetiapine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 256-264.	1.3	49
301	Depressive symptoms and viral clearance in patients receiving interferon- $\alpha$ and ribavirin for hepatitis C. <i>Brain, Behavior, and Immunity</i> , 2005, 19, 23-27.	2.0	137
302	Carbon-11 HOMADAM: A novel PET radiotracer for imaging serotonin transporters. <i>Nuclear Medicine and Biology</i> , 2005, 32, 211-224.	0.3	30
303	Synthesis and biological evaluation of trans-3-phenyl-1-indanamines as potential norepinephrine transporter imaging agents. <i>Nuclear Medicine and Biology</i> , 2005, 32, 593-605.	0.3	4
304	Alterations in diurnal cortisol rhythm and acoustic startle response in nonhuman primates with adverse rearing. <i>Biological Psychiatry</i> , 2005, 57, 373-381.	0.7	162
305	Anterior Cingulate Activation and Error Processing During Interferon-Alpha Treatment. <i>Biological Psychiatry</i> , 2005, 58, 190-196.	0.7	204
306	Mood Disorders in the Medically Ill: Scientific Review and Recommendations. <i>Biological Psychiatry</i> , 2005, 58, 175-189.	0.7	913

#	ARTICLE	IF	CITATIONS
307	Virally Mediated Increased Neurotensin 1 Receptor in the Nucleus Accumbens Decreases Behavioral Effects of Mesolimbic System Activation. <i>Journal of Neuroscience</i> , 2005, 25, 11748-11756.	1.7	26
308	Depression During Pegylated Interferon-Alpha Plus Ribavirin Therapy. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 41-48.	1.1	262
309	Aripiprazole Augmentation of Antidepressants for the Treatment of Partially Responding and Nonresponding Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1216-1220.	1.1	90
310	The neurobiology of depression: inroads to treatment and new drug discovery. <i>Journal of Clinical Psychiatry</i> , 2005, 66 Suppl 7, 5-13.	1.1	109
311	Use of atypical antipsychotics in refractory depression and anxiety. <i>Journal of Clinical Psychiatry</i> , 2005, 66 Suppl 8, 13-21.	1.1	28
312	Neurotensin, Schizophrenia, and Antipsychotic Drug Action. <i>International Review of Neurobiology</i> , 2004, 59, 327-349.	0.9	46
313	Neurotensin Receptor Antagonist SR 142948A Alters Fos Expression and Extrapyrmidal Side Effect Profile of Typical and Atypical Antipsychotic Drugs. <i>Neuropsychopharmacology</i> , 2004, 29, 2200-2207.	2.8	23
314	Prediction of Antidepressant Response to Milnacipran by Norepinephrine Transporter Gene Polymorphisms. <i>American Journal of Psychiatry</i> , 2004, 161, 1575-1580.	4.0	153
315	Spontaneous Withdrawal from the Triazolobenzodiazepine Alprazolam Increases Cortical Corticotropin-Releasing Factor mRNA Expression. <i>Journal of Neuroscience</i> , 2004, 24, 9303-9312.	1.7	19
316	Cerebrospinal Fluid Corticotropin-Releasing Factor and Perceived Early-Life Stress in Depressed Patients and Healthy Control Subjects. <i>Neuropsychopharmacology</i> , 2004, 29, 777-784.	2.8	180
317	Plasma Homocysteine and Immune Activation in Patients with Malignant Melanoma Undergoing Treatment with IFN- $\alpha$ . <i>Journal of Interferon and Cytokine Research</i> , 2004, 24, 311-317.	0.5	3
318	Importance of Studying the Contributions of Early Adverse Experience to Neurobiological Findings in Depression. <i>Neuropsychopharmacology</i> , 2004, 29, 641-648.	2.8	453
319	Interdose Elevation in Plasma Cortisol During Chronic Treatment with Alprazolam but not Lorazepam in the Elderly. <i>Neuropsychopharmacology</i> , 2004, 29, 605-611.	2.8	14
320	Alterations in platelet serotonin transporter binding in women with postpartum onset major depression. <i>Journal of Psychiatric Research</i> , 2004, 38, 467-473.	1.5	36
321	Increased responsiveness of presumed 5-HT cells to citalopram in adult rats subjected to prolonged maternal separation relative to brief separation. <i>Psychopharmacology</i> , 2004, 176, 248-255.	1.5	86
322	Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. <i>Biological Psychiatry</i> , 2004, 55, 320-322.	0.7	154
323	Long-term adaptations in glucocorticoid receptor and mineralocorticoid receptor mRNA and negative feedback on the hypothalamo-pituitary-adrenal axis following neonatal maternal separation. <i>Biological Psychiatry</i> , 2004, 55, 367-375.	0.7	316
324	Increased cerebrospinal fluid corticotropin-releasing factor concentrations during tryptophan depletion in healthy adults. <i>Biological Psychiatry</i> , 2004, 56, 531-534.	0.7	22

#	ARTICLE	IF	CITATIONS
325	Synthesis and biological evaluation of [ <sup>11</sup> C]talopram and [ <sup>11</sup> C]talsupram: candidate PET ligands for the norepinephrine transporter. <i>Nuclear Medicine and Biology</i> , 2004, 31, 705-718.	0.3	38
326	Pituitary-adrenal responses to standard and low-dose dexamethasone suppression tests in adult survivors of child abuse. <i>Biological Psychiatry</i> , 2004, 55, 10-20.	0.7	161
327	Introduction <i>Advances in the Treatment of Mood and Anxiety Disorders</i> . <i>CNS Spectrums</i> , 2004, 9, 5-5.	0.7	0
328	Pharmacologic Differences Among the SSRIs: Focus on Monoamine Transporters and the HPA Axis. <i>CNS Spectrums</i> , 2004, 9, 23-31.	0.7	85
329	Are Mood Disorders and Obesity Related? A Review for the Mental Health Professional. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 634-651.	1.1	528
330	Treatment of Posttraumatic Stress Disorder With Phenytoin. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1559-1564.	1.1	54
331	Neurobiological consequences of childhood trauma. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 1, 18-28.	1.1	143
332	The neurobiology of bipolar disorder. <i>American Journal of Medical Genetics Part A</i> , 2003, 123C, 76-84.	2.4	51
333	Reply to 'Editorial policies on financial disclosure'. <i>Nature Neuroscience</i> , 2003, 6, 1000-1001.	7.1	4
334	Serotonin Transporter: A Potential Substrate in the Biology of Suicide. <i>Neuropsychopharmacology</i> , 2003, 28, 613-619.	2.8	97
335	Cortisol concentrations in 12- to 18-Month-Old infants: stability over time, location, and stressor. <i>Biological Psychiatry</i> , 2003, 54, 719-726.	0.7	80
336	Depression and Bipolar Support Alliance Consensus Statement on the Unmet Needs in Diagnosis and Treatment of Mood Disorders in Children and Adolescents. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2003, 42, 1494-1503.	0.3	86
337	Synthesis and Characterization of Iodine-123 Labeled 2[ <sup>2</sup> -Carbomethoxy-3[ <sup>2</sup> -(4-((Z)-2-iodoethenyl)phenyl)nortropane. A Ligand for in Vivo Imaging of Serotonin Transporters by Single-Photon-Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 925-935.	2.9	35
338	Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies. <i>Physiology and Behavior</i> , 2003, 79, 471-478.	1.0	111
339	Interferon-alpha-induced changes in tryptophan metabolism. <i>Biological Psychiatry</i> , 2003, 54, 906-914.	0.7	449
340	Epidemiology of comorbid coronary artery disease and depression. <i>Biological Psychiatry</i> , 2003, 54, 227-240.	0.7	459
341	Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events. <i>Circulation</i> , 2003, 108, 939-944.	1.6	306
342	The Effects of Chronic Treatment with the Mood Stabilizers Valproic Acid and Lithium on Corticotropin-Releasing Factor Neuronal Systems. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 305, 434-439.	1.3	45

#	ARTICLE	IF	CITATIONS
343	Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 14293-14296.	3.3	729
344	The Corticotropin-Releasing Factor1 Receptor Antagonist R121919 Attenuates the Behavioral and Endocrine Responses to Stress. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 874-880.	1.3	99
345	Cerebrospinal Fluid Corticotropin-Releasing Factor (CRF) and Vasopressin Concentrations Predict Pituitary Response in the CRF Stimulation Test: A Multiple Regression Analysis. <i>Neuropsychopharmacology</i> , 2003, 28, 569-576.	2.8	44
346	Maintenance Efficacy of Divalproex in the Prevention of Bipolar Depression. <i>Neuropsychopharmacology</i> , 2003, 28, 1374-1382.	2.8	153
347	Association of Exaggerated HPA Axis Response to the Initial Injection of Interferon-Alpha With Development of Depression During Interferon-Alpha Therapy. <i>American Journal of Psychiatry</i> , 2003, 160, 1342-1345.	4.0	285
348	Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Affective Disorders. <i>Neuropsychopharmacology</i> , 2003, 28, 201-205.	2.8	58
349	Divalproex in the Treatment of Impulsive Aggression: Efficacy in Cluster B Personality Disorders. <i>Neuropsychopharmacology</i> , 2003, 28, 1186-1197.	2.8	231
350	Action of Three Ectopeptidases on Corticotropin-Releasing Factor: Metabolism and Functional Aspects. <i>Neuropsychopharmacology</i> , 2003, 28, 22-33.	2.8	11
351	Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?. <i>Seminars in Clinical Neuropsychiatry</i> , 2003, 8, 94-108.	1.9	17
352	Neurobiology of Early-Life Stress. <i>Psychiatric Annals</i> , 2003, 33, 18-26.	0.1	35
353	The Pharmacokinetics of Sertraline Excretion Into Human Breast Milk. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 73-80.	1.1	76
354	Safety of Available Agents Used to Treat Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 532-539.	1.1	75
355	Anxiolytics: past, present, and future agents. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 3, 3-6.	1.1	11
356	Overview of the safety of citalopram. <i>Psychopharmacology Bulletin</i> , 2003, 37, 96-121.	0.0	18
357	Advancing the treatment of mood and anxiety disorders: the first 10 years' experience with paroxetine. <i>Psychopharmacology Bulletin</i> , 2003, 37 Suppl 1, 6-7.	0.0	2
358	Neuropharmacology of paroxetine. <i>Psychopharmacology Bulletin</i> , 2003, 37 Suppl 1, 8-18.	0.0	12
359	Improving antidepressant adherence. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 18, 25-30.	1.1	8
360	The role of GABA in the pathophysiology and treatment of anxiety disorders. <i>Psychopharmacology Bulletin</i> , 2003, 37, 133-46.	0.0	178

#	ARTICLE	IF	CITATIONS
361	Cerebrospinal Fluid Concentrations of Biogenic Amines and Corticotropin-releasing Factor in Adolescent Non-human Primates as a Function of the Timing of Adverse Early Rearing. <i>Stress</i> , 2002, 5, 185-193.	0.8	43
362	Effect of <i>Hypericum perforatum</i> (St John's Wort) in Major Depressive Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 1807.	3.8	417
363	Childhood Trauma Associated With Smaller Hippocampal Volume in Women With Major Depression. <i>American Journal of Psychiatry</i> , 2002, 159, 2072-2080.	4.0	742
364	Regulation of Corticotropin-Releasing Factor Neuronal Systems and Hypothalamic-Pituitary-Adrenal Axis Activity by Stress and Chronic Antidepressant Treatment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 300, 1085-1092.	1.3	110
365	Parental Depression: Animal Models of an Adverse Life Event. <i>American Journal of Psychiatry</i> , 2002, 159, 1265-1283.	4.0	234
366	Inhibition of Norepinephrine Uptake in Patients With Major Depression Treated With Paroxetine. <i>American Journal of Psychiatry</i> , 2002, 159, 1702-1710.	4.0	93
367	Comorbidity of Mood and Anxiety Disorders: The Rule, Not the Exception?. <i>American Journal of Psychiatry</i> , 2002, 159, 3-4.	4.0	62
368	National Depressive and Manic-Depressive Association Consensus Statement on the Use of Placebo in Clinical Trials of Mood Disorders. <i>Archives of General Psychiatry</i> , 2002, 59, 262.	13.8	134
369	Does psychosocial functioning improve independent of depressive symptoms? a comparison of nefazodone, psychotherapy, and their combination. <i>Biological Psychiatry</i> , 2002, 51, 123-133.	0.7	204
370	Neurotensin receptor binding abnormalities in the entorhinal cortex in schizophrenia and affective disorders. <i>Biological Psychiatry</i> , 2002, 51, 795-800.	0.7	19
371	Developing novel treatments for mood disorders: accelerating discovery. <i>Biological Psychiatry</i> , 2002, 52, 589-609.	0.7	68
372	Neurotensin: an endogenous antipsychotic?. <i>Current Opinion in Pharmacology</i> , 2002, 2, 99-103.	1.7	48
373	Response. <i>Neuropsychopharmacology</i> , 2002, 26, 413-414.	2.8	1
374	Neurobehavioral Effects of Interferon- $\gamma$ in Cancer Patients Phenomenology and Paroxetine Responsiveness of Symptom Dimensions. <i>Neuropsychopharmacology</i> , 2002, 26, 643-652.	2.8	680
375	Differing concentrations of corticotropin-releasing factor and oxytocin in the cerebrospinal fluid of bonnet and pigtail macaques. <i>Psychoneuroendocrinology</i> , 2002, 27, 651-660.	1.3	91
376	New directions in the development of antidepressants: the interface of neurobiology and psychiatry. <i>Human Psychopharmacology</i> , 2002, 17, S13-S16.	0.7	42
377	The role of early adverse experience and adulthood stress in the prediction of neuroendocrine stress reactivity in women: A multiple regression analysis. <i>Depression and Anxiety</i> , 2002, 15, 117-125.	2.0	389
378	Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment. <i>Depression and Anxiety</i> , 2002, 15, 91-101.	2.0	38

#	ARTICLE	IF	CITATIONS
379	Effects of neurotensin receptor antagonism on latent inhibition in Sprague-Dawley rats. <i>Psychopharmacology</i> , 2002, 161, 288-295.	1.5	22
380	Exposure to an Antisense Oligonucleotide Decreases Corticotropin-Releasing Factor Receptor Binding in Rat Pituitary Cultures. <i>Journal of Neurochemistry</i> , 2002, 64, 2358-2361.	2.1	6
381	Corticotropin-Releasing Factor (CRF), CRF-Binding Protein (CRF-BP), and CRF/CRF-BP Complex in Alzheimer's Disease and Control Postmortem Human Brain. <i>Journal of Neurochemistry</i> , 2002, 68, 2053-2060.	2.1	49
382	Treatment of mood disorders. <i>Nature Neuroscience</i> , 2002, 5, 1068-1070.	7.1	237
383	Neurobiology of early life stress: Rodent studies. <i>Seminars in Clinical Neuropsychiatry</i> , 2002, 7, 89-95.	1.9	122
384	Neurobiology of early life stress: Clinical studies. <i>Seminars in Clinical Neuropsychiatry</i> , 2002, 7, 147-159.	1.9	248
385	Efficacy and Tolerability of Controlled-Release and Immediate-Release Paroxetine in the Treatment of Depression. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 577-584.	1.1	89
386	Partial Response and Nonresponse to Antidepressant Therapy. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 826-837.	1.1	170
387	Recent advances in the neurobiology of depression. <i>Psychopharmacology Bulletin</i> , 2002, 36 Suppl 2, 6-23.	0.0	31
388	Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. <i>Journal of Clinical Psychiatry</i> , 2002, 63 Suppl 13, 5-11.	1.1	31
389	Duloxetine for the treatment of major depressive disorder. <i>Psychopharmacology Bulletin</i> , 2002, 36, 106-32.	0.0	130
390	Clinical Pharmacokinetics of Quetiapine. <i>Clinical Pharmacokinetics</i> , 2001, 40, 509-522.	1.6	319
391	Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. <i>Biological Psychiatry</i> , 2001, 50, 345-350.	0.7	434
392	The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. <i>Biological Psychiatry</i> , 2001, 49, 1023-1039.	0.7	2,337
393	Variable foraging demand rearing: sustained elevations in cisternal cerebrospinal fluid corticotropin-releasing factor concentrations in adult primates. <i>Biological Psychiatry</i> , 2001, 50, 200-204.	0.7	118
394	The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. <i>Biological Psychiatry</i> , 2001, 50, 856-872.	0.7	80
395	New perspectives on the neurobiology of schizophrenia and the role of atypical antipsychotics: introduction. <i>Biological Psychiatry</i> , 2001, 50, 823-824.	0.7	2
396	Paroxetine for the Prevention of Depression Induced by High-Dose Interferon Alfa. <i>New England Journal of Medicine</i> , 2001, 344, 961-966.	13.9	1,006

#	ARTICLE	IF	CITATIONS
397	Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. <i>Nuclear Medicine and Biology</i> , 2001, 28, 187-195.	0.3	27
398	The Rage to Know, the Rage to Teach, and the Rage to Heal: What Is the Proper Balance?. <i>CNS Spectrums</i> , 2001, 6, 459-459.	0.7	0
399	Peptides and Psychiatry. , 2001, , 11189-11195.		1
400	Enhanced Neurotensin Neurotransmission Is Involved in the Clinically Relevant Behavioral Effects of Antipsychotic Drugs: Evidence from Animal Models of Sensorimotor Gating. <i>Journal of Neuroscience</i> , 2001, 21, 601-608.	1.7	73
401	How Will We Solve the Critical Shortage of Clinicianâ€“Scientists in Psychiatry?. <i>CNS Spectrums</i> , 2001, 6, 889-889.	0.7	0
402	The Development of New Technologies in Medicine: What Will the Impact Be in Psychiatry?. <i>CNS Spectrums</i> , 2001, 6, 21-21.	0.7	0
403	An Old Transmitter in a New Millennium. <i>CNS Spectrums</i> , 2001, 6, 655-655.	0.7	0
404	An Evaluation of Risperidone Drug Interactions. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 408-416.	0.7	37
405	Progress in the Battle With the Black Dog: Advances in the Treatment of Depression. <i>American Journal of Psychiatry</i> , 2001, 158, 1555-1557.	4.0	9
406	Altered Pituitary-Adrenal Axis Responses to Provocative Challenge Tests in Adult Survivors of Childhood Abuse. <i>American Journal of Psychiatry</i> , 2001, 158, 575-581.	4.0	650
407	Role of Norepinephrine in the Pathophysiology of Neuropsychiatric Disorders. <i>CNS Spectrums</i> , 2001, 6, 663-670.	0.7	49
408	The effects of glutamate receptor agonists on neurotensin release using in vivo microdialysis. <i>European Journal of Pharmacology</i> , 2001, 411, 129-134.	1.7	9
409	CSF thyrotropin-releasing hormone concentrations differ in patients with schizoaffective disorder from patients with schizophrenia or mood disorders. <i>Journal of Psychiatric Research</i> , 2001, 35, 287-291.	1.5	10
410	Effects of Sodium Valproate on Corticotropin-Releasing Factor Systems in Rat Brain. <i>Neuropsychopharmacology</i> , 2001, 24, 624-631.	2.8	33
411	The evaluation and treatment of depression in primary care. <i>Clinical Cornerstone</i> , 2001, 3, 10-20.	1.0	2
412	NEUROKININ1RECEPTORANTAGONISTS ASPOTENTIALANTIDEPRESSANTS. <i>Annual Review of Pharmacology and Toxicology</i> , 2001, 41, 877-906.	4.2	109
413	Chromosome 22q and the mindâ€“brain interface. <i>Neurology</i> , 2001, 57, 377-378.	1.5	2
414	Higher Than Normal Plasma Interleukin-6 Concentrations in Cancer Patients With Depression: Preliminary Findings. <i>American Journal of Psychiatry</i> , 2001, 158, 1252-1257.	4.0	399



#	ARTICLE	IF	CITATIONS
415	Double-Blind, Placebo-Controlled Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression. <i>American Journal of Psychiatry</i> , 2001, 158, 906-912.	4.0	381
416	The Depressed Suicidal Patient. <i>Annals of the New York Academy of Sciences</i> , 2001, 932, 1-23.	1.8	29
417	One Brain, But Different Clinical Disciplines: Should Psychiatry and Neurology Be United?. <i>CNS Spectrums</i> , 2000, 5, 17-17.	0.7	0
418	The Role of Patient Advocacy in Funding Policy. <i>CNS Spectrums</i> , 2000, 5, 17-20.	0.7	0
419	Platelet Reactivity in Depressed Patients Treated With Paroxetine. <i>Archives of General Psychiatry</i> , 2000, 57, 875.	13.8	189
420	More than one-half of a decade of experience with venlafaxine dual serotonin-norepinephrine reuptake inhibitor. <i>Depression and Anxiety</i> , 2000, 12, 1-1.	2.0	0
421	Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. <i>Depression and Anxiety</i> , 2000, 12, 2-19.	2.0	746
422	Prednisone augmentation in treatment-resistant depression with fatigue and hypocortisolemia: A case series. <i>Depression and Anxiety</i> , 2000, 12, 44-50.	2.0	43
423	Neurobiology of posttraumatic stress disorder. <i>Current Opinion in Neurobiology</i> , 2000, 10, 211-218.	2.0	192
424	The effects of acute antipsychotic drug administration on the neurotensin system of the developing rat brain. <i>Developmental Brain Research</i> , 2000, 124, 1-10.	2.1	2
425	Sensitivity to glucocorticoid-mediated fast-feedback regulation of the hypothalamic-pituitary-adrenal axis is dependent upon stressor specific neurocircuitry. <i>Brain Research</i> , 2000, 870, 87-101.	1.1	92
426	Increased corticotropin-releasing factor concentrations in the bed nucleus of the stria terminalis of anhedonic rats. <i>European Journal of Pharmacology</i> , 2000, 401, 39-46.	1.7	87
427	A comparison of plasma alprazolam concentrations following different routes of chronic administration in the Sprague-Dawley rat: implications for psychotropic drug research. <i>Psychopharmacology</i> , 2000, 151, 72-76.	1.5	4
428	Chronic Administration of the Triazolobenzodiazepine Alprazolam Produces Opposite Effects on Corticotropin-Releasing Factor and Urocortin Neuronal Systems. <i>Journal of Neuroscience</i> , 2000, 20, 1240-1248.	1.7	112
429	Cuba II: A Land Stuck in Time. <i>CNS Spectrums</i> , 2000, 5, 17-17.	0.7	0
430	Cuba: A Land Stuck in Time. <i>CNS Spectrums</i> , 2000, 5, 17-17.	0.7	1
431	A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression. <i>New England Journal of Medicine</i> , 2000, 342, 1462-1470.	13.9	1,188
432	Paroxetine binding to the rat norepinephrine transporter in vivo. <i>Biological Psychiatry</i> , 2000, 47, 842-845.	0.7	60

#	ARTICLE	IF	CITATIONS
433	Growth hormone response to clonidine in adversely reared young adult primates: relationship to serial cerebrospinal fluid corticotropin-releasing factor concentrations. <i>Psychiatry Research</i> , 2000, 95, 93-102.	1.7	32
434	The neurobiology of urocortin. <i>Regulatory Peptides</i> , 2000, 93, 85-92.	1.9	136
435	Introduction. <i>American Heart Journal</i> , 2000, 140, S55-S56.	1.2	2
436	Are platelets the link between depression and ischemic heart disease?. <i>American Heart Journal</i> , 2000, 140, S57-S62.	1.2	184
437	Depression really does hurt your heart: stress, depression, and cardiovascular disease. <i>Progress in Brain Research</i> , 2000, 122, 43-59.	0.9	38
438	Long-term behavioral and neuroendocrine adaptations to adverse early experience. <i>Progress in Brain Research</i> , 2000, 122, 81-103.	0.9	577
439	Effects of early adverse experiences on brain structure and function: clinical implications. <i>Biological Psychiatry</i> , 2000, 48, 778-790.	0.7	439
440	Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. <i>Depression and Anxiety</i> , 2000, 12, 2-19.	2.0	65
441	Placebo-Controlled Study of Fluvoxamine in the Treatment of Patients With Compulsive Buying. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 362-366.	0.7	140
442	Corticotropin-releasing factor antagonists as novel psychotherapeutics. <i>Drugs of the Future</i> , 2000, 25, 0923.	0.0	9
443	A Major Step Backward for the American Medical Association. <i>CNS Spectrums</i> , 1999, 4, 16-16.	0.7	0
444	How Are You?. <i>CNS Spectrums</i> , 1999, 4, 18-18.	0.7	0
445	Corticotropin-releasing factor antagonists in affective disorders. <i>Expert Opinion on Investigational Drugs</i> , 1999, 8, 1849-1858.	1.9	32
446	Corticotropin-Releasing Factor Antagonists. <i>CNS Drugs</i> , 1999, 12, 85-92.	2.7	20
447	Neurotensin studies in alcohol naive, preferring and non-preferring rats. <i>Neuroscience</i> , 1999, 93, 227-236.	1.1	42
448	Long-Term Behavioral Effects of Repetitive Pain in Neonatal Rat Pups. <i>Physiology and Behavior</i> , 1999, 66, 627-637.	1.0	385
449	Hyperintense lesions on magnetic resonance images in bipolar disorder. <i>Biological Psychiatry</i> , 1999, 45, 965-971.	0.7	88
450	Does neurotensin mediate the effects of antipsychotic drugs?. <i>Biological Psychiatry</i> , 1999, 46, 340-351.	0.7	77

#	ARTICLE	IF	CITATIONS
451	Role of norepinephrine in the pathophysiology and treatment of mood disorders. <i>Biological Psychiatry</i> , 1999, 46, 1219-1233.	0.7	254
452	The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. <i>Biological Psychiatry</i> , 1999, 46, 1509-1522.	0.7	465
453	The role of corticotropin-releasing factor in depression and anxiety disorders. <i>Journal of Endocrinology</i> , 1999, 160, 1-12.	1.2	1,263
454	The effects of neonatal stress on brain development: Implications for psychopathology. <i>Development and Psychopathology</i> , 1999, 11, 545-565.	1.4	181
455	The Preeminent Role of Neuropeptide Systems in the Early Pathophysiology of Alzheimer Disease. <i>Archives of General Psychiatry</i> , 1999, 56, 991.	13.8	8
456	The Neurobiology of Depression. <i>Scientific American</i> , 1998, 278, 42-49.	1.0	274
457	Mode matches in hydrophobic free energy eigenfunctions predict peptide-protein interactions. <i>Biopolymers</i> , 1998, 46, 89-101.	1.2	32
458	New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone, and mirtazapine. <i>Depression and Anxiety</i> , 1998, 7, 24-32.	2.0	73
459	The serotonin transporter and depression. <i>Depression and Anxiety</i> , 1998, 8, 5-12.	2.0	98
460	Depression and cardiac disease. <i>Depression and Anxiety</i> , 1998, 8, 71-79.	2.0	82
461	Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: Response to amitriptyline treatment. <i>Depression and Anxiety</i> , 1998, 8, 71-79.	2.0	155
462	Assessment and treatment of depression in the cancer patient. <i>Journal of Psychosomatic Research</i> , 1998, 45, 215-237.	1.2	160
463	Reduced brain serotonin transporter availability in major depression as measured by [ <sup>123</sup> I]-2 $\beta$ -carbomethoxy-3-(4-iodophenyl)tropane and single photon emission computed tomography. <i>Biological Psychiatry</i> , 1998, 44, 1090-1098.	0.7	456
464	PSYCHONEUROENDOCRINOLOGY OF DEPRESSION. <i>Psychiatric Clinics of North America</i> , 1998, 21, 293-307.	0.7	522
465	The Relationship of Depression to Cardiovascular Disease. <i>Archives of General Psychiatry</i> , 1998, 55, 580.	13.8	1,372
466	Neurosarcoidosis as a Cause of Refractory Psychosis: A Complicated Case Report. <i>American Journal of Psychiatry</i> , 1998, 155, 1106-1108.	4.0	32
467	On Mentoring. <i>CNS Spectrums</i> , 1998, 3, 17-17.	0.7	1
468	Cerebrospinal Fluid Concentrations of Somatostatin and Biogenic Amines in Grown Primates Reared by Mothers Exposed to Manipulated Foraging Conditions. <i>Archives of General Psychiatry</i> , 1998, 55, 473.	13.8	138

#	ARTICLE	IF	CITATIONS
469	Challenges in the Classification and Treatment of Trichotillomania. CNS Spectrums, 1998, 3, 30-35.	0.7	9
470	The Importance of Longitudinal Studies in Psychiatric Disorders. CNS Spectrums, 1998, 3, 19-19, 70.	0.7	0
471	Polypharmacology in Psychiatry: Good or Bad?. CNS Spectrums, 1998, 3, 19-19.	0.7	3
472	Psychoanalysis, Psychodynamic Psychotherapy, and Psychopharmacology. CNS Spectrums, 1998, 3, 18-18,74.	0.7	0
473	Placebo in the Evaluation of Psychiatric Treatments. CNS Spectrums, 1998, 3, 18-19.	0.7	0
474	Symptoms Vs Syndromes in the Treatment of Psychiatric Disorders. CNS Spectrums, 1998, 3, 21-21.	0.7	59
475	The National Bioethics Advisory Commission and Its Report. CNS Spectrums, 1998, 3, 13-13.	0.7	1
476	The Greatest Kid Ever. CNS Spectrums, 1998, 3, 14-15.	0.7	0
477	Regional Neuropeptide Pathology in Alzheimer's Disease: Corticotropin-Releasing Factor and Somatostatin. Journal of Alzheimer's Disease, 1998, 1, 91-105.	1.2	17
478	Mode matches in hydrophobic free energy eigenfunctions predict peptide-protein interactions. , 1998, 46, 89.		1
479	Depression and cardiac disease. Depression and Anxiety, 1998, 8, 71-79.	2.0	1
480	â– REVIEW : Corticotropin-releasing Factor, Stress, and Depression. Neuroscientist, 1997, 3, 186-194.	2.6	41
481	Too Much Stuff, Too Little Time. CNS Spectrums, 1997, 2, 70-70.	0.7	0
482	Striking a Balance Between Clinical Medical School Departments and the Industry. CNS Spectrums, 1997, 2, 65-66.	0.7	7
483	Striking a Balance With the Pharmaceutical Industry: Part II. CNS Spectrums, 1997, 2, 68-68.	0.7	0
484	The Emerging and Disheartening Picture of the Consequences of Child Abuse and Neglect: Implications for Psychiatric Morbidity. CNS Spectrums, 1997, 2, 68-70.	0.7	1
485	Managed Care in Psychiatry: Panacea or Pariah?. CNS Spectrums, 1997, 2, 13-62.	0.7	0
486	Depression Must be Invisible. CNS Spectrums, 1997, 2, 70-70.	0.7	0

#	ARTICLE	IF	CITATIONS
487	The Role of Early Adverse Life Events in the Etiology of Depression and Posttraumatic Stress Disorder.. Annals of the New York Academy of Sciences, 1997, 821, 194-207.	1.8	172
488	Dexamethasone suppression test identifies a subset of elderly depressed patients with reduced platelet serotonin transport and resistance to imipramine inhibition of transport. Depression and Anxiety, 1997, 6, 19-25.	2.0	10
489	Estrogen Replacement and Response to Fluoxetine in a Multicenter Geriatric Depression Trial. American Journal of Geriatric Psychiatry, 1997, 5, 97-106.	0.6	148
490	Cancer and Depression: Theory and Treatment. Psychiatric Annals, 1997, 27, 360-364.	0.1	27
491	Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biological Psychiatry, 1996, 39, 703-707.	0.7	78
492	Apolipoprotein E- $\mu$ 4 frequency in geriatric depression. Biological Psychiatry, 1996, 40, 69-71.	0.7	116
493	Postmortem and Cerebrospinal Fluid Studies of Corticotropin-releasing Factor in Humansa. Annals of the New York Academy of Sciences, 1996, 780, 96-105.	1.8	37
494	The simultaneous determination of neurotensin and its major fragments by on-line trace enrichment HPLC with electrochemical detection. Life Sciences, 1996, 59, 911-920.	2.0	4
495	Venlafaxine: A novel antidepressant that has a dual mechanism of action. Depression, 1996, 4, 48-56.	0.7	82
496	Depression and Endocrine Disorders: Focus on the Thyroid and Adrenal System. British Journal of Psychiatry, 1996, 168, 123-128.	1.7	125
497	Dr. Nemeroff and Colleagues Reply. American Journal of Psychiatry, 1996, 153, 1656-1657.	4.0	111
498	???Normal Pressure??? Pseudotumor Cerebri. Journal of Neuro-Ophthalmology, 1996, 16, 241???246.	0.4	7
499	Impact of Physical Illness on Quality of Life and Antidepressant Response in Geriatric Major Depression. Journal of the American Geriatrics Society, 1996, 44, 1220-1225.	1.3	56
500	Endocrine and behavioral effects of airpuff-startle in rats. Psychoneuroendocrinology, 1996, 21, 391-400.	1.3	51
501	Augmentation strategies in patients with refractory depression. , 1996, 4, 169-181.		56
502	Is there a relationship between baseline and treatment-associated changes in [H]-IMI platelet binding and clinical response in major depression?. Neuropsychopharmacology, 1996, 14, 47-53.	2.8	9
503	Section Review: Central & Peripheral Nervous Systems: Selective serotonin reuptake inhibitors in the treatment of depression. Expert Opinion on Investigational Drugs, 1996, 5, 101-108.	1.9	6
504	Migraine and Affective Disorders. Psychiatric Annals, 1996, 26, .	0.1	0

#	ARTICLE	IF	CITATIONS
505	Adrenal Function in Major Depression. , 1995, 5, 91-96.		10
506	Clinical Response Predictors in a Double-Blind, Placebo-Controlled Trial of Fluoxetine for Geriatric Major Depression. <i>International Psychogeriatrics</i> , 1995, 7, 41-53.	0.6	33
507	[26] Immunological, pharmacological, and electrophysiological detection of T-cell-modulating properties of substances of abuse. <i>Methods in Neurosciences</i> , 1995, 24, 410-423.	0.5	0
508	Ontogeny of the effect of antipsychotic drug treatment on neurotensin concentrations in the rat brain. <i>Synapse</i> , 1995, 20, 244-248.	0.6	3
509	Regulation of Corticotropin-Releasing Factor Secretion and Synthesis in the Human Neuroblastoma Clones- BE(2)-M17 and BE(2)-C. <i>Journal of Neuroendocrinology</i> , 1995, 7, 461-466.	1.2	16
510	Benzodiazepine Sensitivity in Panic Disorder: Effects of Chronic Alprazolam Treatment. <i>Neuropsychopharmacology</i> , 1995, 12, 147-157.	2.8	52
511	Sertraline in the treatment of women with postpartum major depression. <i>Depression</i> , 1995, 3, 49-55.	0.7	84
512	Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. <i>Depression</i> , 1995, 3, 163-169.	0.7	39
513	Chronic haloperidol-induced changes in regional dopamine release and metabolism and neurotensin content in rats. <i>Brain Research</i> , 1995, 704, 202-209.	1.1	31
514	The serotonergic antidepressant nefazodone inhibits the serotonin transporter: In vivo and ex vivo studies. <i>Life Sciences</i> , 1995, 57, PL373-PL380.	2.0	23
515	Cerebrospinal fluid corticotropin-releasing hormone, vasopressin, and oxytocin concentrations in treated patients with major depression and controls. <i>Biological Psychiatry</i> , 1995, 38, 330-335.	0.7	75
516	Women at risk for postpartum-onset major depression. <i>American Journal of Obstetrics and Gynecology</i> , 1995, 173, 639-645.	0.7	191
517	Anatomy and Mechanisms of Neurotensin-Dopamine Interactions in the Central Nervous System. <i>Annals of the New York Academy of Sciences</i> , 1995, 757, 377-389.	1.8	54
518	Benzodiazepine Sensitivity in Panic Disorder: Effects of Chronic Alprazolam Treatment. <i>Neuropsychopharmacology</i> , 1995, 12, 147-157.	2.8	7
519	Psychological and neurobiological consequences of trauma. , 1994, , 123-151.		0
520	Interleukin-1 $\gamma$ induces corticotropin-releasing factor secretion and synthesis from NPLC-KC cells through various second messenger pathways. <i>Synapse</i> , 1994, 18, 354-358.	0.6	8
521	Tricyclics and newer antidepressant medications: Treatment options for treatment-resistant depressions. <i>Depression</i> , 1994, 2, 152-168.	0.7	17
522	Stress and psychiatric disorders. <i>Seminars in Neuroscience</i> , 1994, 6, 271-280.	2.3	31

#	ARTICLE	IF	CITATIONS
523	Neurochemical Correlates of Sympathetic Activation during Severe Alcohol Withdrawal. <i>Alcoholism: Clinical and Experimental Research</i> , 1994, 18, 1312-1316.	1.4	68
524	Cerebrospinal fluid TRH immunoreactivity in anorexia nervosa. <i>Biological Psychiatry</i> , 1994, 35, 48-53.	0.7	19
525	Cortical and subcortical neuropeptides in Alzheimer's disease. <i>Neurobiology of Aging</i> , 1994, 15, 589-595.	1.5	21
526	Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia. <i>Schizophrenia Research</i> , 1994, 12, 43-51.	1.1	21
527	Contemporary management of depression. <i>American Journal of Medicine</i> , 1994, 97, S24-S32.	0.6	106
528	Corticotropin-releasing factor is secreted in the BE(2)-C neuroblastoma cell and is responsive to forskolin. <i>Life Sciences</i> , 1994, 54, 1825-1829.	2.0	4
529	The BE (2)-M17 neuroblastoma cell line synthesizes and secretes corticotropin-releasing factor. <i>Brain Research</i> , 1994, 654, 159-162.	1.1	13
530	The neurobiological consequences of early traumatic experiences: focus on corticotropin-releasing factor. <i>European Neuropsychopharmacology</i> , 1994, 4, 255-256.	0.3	4
531	Depression and anxiety: Role of the locus coeruleus and corticotropin-releasing factor. <i>Brain Research Bulletin</i> , 1994, 35, 561-572.	1.4	149
532	CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. <i>Schizophrenia Research</i> , 1994, 12, 35-41.	1.1	51
533	Cerebrospinal fluid somatostatin concentrations in schizophrenia and schizoaffective disorder: the effects of antipsychotic treatment. <i>Schizophrenia Research</i> , 1994, 13, 173-177.	1.1	8
534	Potential Corticotropin-Releasing Factor Pathways in the Rat Brain as Determined by Bilateral Electrolytic Lesions of the Central Amygdaloid Nucleus and the Paraventricular Nucleus of the Hypothalamus. <i>Journal of Neuroendocrinology</i> , 1993, 5, 95-98.	1.2	55
535	The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: Implications for a role for CRF in the pathogenesis of anxiety disorders. <i>Journal of Psychiatric Research</i> , 1993, 27, 209-220.	1.5	27
536	Tritiated platelet imipramine binding and treatment response in depressed outpatients. <i>Depression</i> , 1993, 1, 20-23.	0.7	16
537	MRI detection of abnormality in the corpus callosum and late-onset depression. <i>Depression</i> , 1993, 1, 108-109.	0.7	0
538	The corticotropin releasing factor stimulation test in patients with major depression: Relationship to dexamethasone suppression test results. <i>Depression</i> , 1993, 1, 133-136.	0.7	18
539	Reduction of cerebellar volume in major depression: A controlled MRI study. <i>Depression</i> , 1993, 1, 156-158.	0.7	42
540	Preclinical evaluation of the putative antidepressant nefazodone. <i>Depression</i> , 1993, 1, 315-323.	0.7	0

#	ARTICLE	IF	CITATIONS
541	Dose response relationship between plasma ACTH and cortisol after the infusion of ACTH1-24. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1993, 242, 240-243.	1.8	2
542	Organic Anxiety Disorder. <i>Psychosomatics</i> , 1993, 34, 181-184.	2.5	5
543	Rhythmicity and response to a.m. and p.m. CRH challenge in elderly subjects. <i>Neurobiology of Aging</i> , 1993, 14, 101-106.	1.5	1
544	Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects. <i>Psychiatry Research</i> , 1993, 46, 1-8.	1.7	75
545	Hypercortisolemia and hippocampal changes in depression. <i>Psychiatry Research</i> , 1993, 47, 163-173.	1.7	244
546	Neurochemical alterations in Rett syndrome. <i>Developmental Brain Research</i> , 1993, 74, 67-72.	2.1	39
547	Effects of gender and social isolation on electroencephalogram and neuroendocrine parameters in rats. <i>Biological Psychiatry</i> , 1993, 33, 358-366.	0.7	41
548	Chronic Continuous or Intermittent Infusion of Cocaine Differentially Alter the Concentration of Neurotensin-like Immunoreactivity in Specific Rat Brain Regions. <i>Neuropsychopharmacology</i> , 1993, 8, 259-265.	2.8	8
549	The Role of Corticotropin-Releasing Factor in the Pathophysiology of Affective and Anxiety Disorders: Laboratory and Clinical Studies. <i>Novartis Foundation Symposium</i> , 1993, 172, 296-316.	1.2	82
550	Adrenal Gland Enlargement in Major Depression. <i>Archives of General Psychiatry</i> , 1992, 49, 384.	13.8	244
551	Substance P, Thyrotropin-releasing Hormone, and Monoamine Metabolites in Cerebrospinal Fluid in Sleep Apnea Patients. <i>The American Review of Respiratory Disease</i> , 1992, 146, 784-786.	2.9	13
552	Neurosciences and neuropsychiatry. <i>Current Opinion in Psychiatry</i> , 1992, 5, 59-61.	3.1	0
553	A new psychobiological theory of attachment: Primum non nocere. <i>Behavioral and Brain Sciences</i> , 1992, 15, 520-521.	0.4	1
554	THE ROLE OF NEUROPEPTIDES IN THE PATHOPHYSIOLOGY OF AFFECTIVE DISORDERS. <i>Clinical Neuropharmacology</i> , 1992, 15, 6A-7A.	0.2	1
555	Reduced platelet tritium-labeled imipramine binding sites in women with premenstrual syndrome. <i>American Journal of Obstetrics and Gynecology</i> , 1992, 167, 168-172.	0.7	46
556	BMY 14802, a potential antipsychotic drug, increases expression of proneurotensin mRNA in the rat striatum. <i>Molecular Brain Research</i> , 1992, 12, 279-284.	2.5	18
557	Cerebrospinal fluid neuropeptides in mood disorder and dementia. <i>Journal of Affective Disorders</i> , 1992, 25, 39-45.	2.0	87
558	Effects of neurotensin on caudate nucleus protein phosphorylation. <i>Regulatory Peptides</i> , 1992, 39, 55-65.	1.9	2



#	ARTICLE	IF	CITATIONS
559	CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse. <i>European Neuropsychopharmacology</i> , 1992, 2, 107-113.	0.3	134
560	RU486 in depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1992, 16, 913-920.	2.5	13
561	Postnatal development of regional binding of corticotropin-releasing factor and adenylate cyclase activity in the rat brain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1992, 16, 581-586.	2.5	25
562	Serotonin antagonists as antipsychotic drugs. <i>European Neuropsychopharmacology</i> , 1992, 2, 287.	0.3	0
563	Cerebrospinal fluid neuropeptides in dementia. <i>Biological Psychiatry</i> , 1992, 32, 452-456.	0.7	20
564	Effects of Chronic Ethanol and Benzodiazepine Treatment and Withdrawal on Corticotropin-releasing Factor Neural Systems. <i>Annals of the New York Academy of Sciences</i> , 1992, 654, 145-152.	1.8	13
565	Neurotensin, Antipsychotic Drugs, and Schizophrenia.. <i>Annals of the New York Academy of Sciences</i> , 1992, 668, 146-156.	1.8	40
566	In vivo assessment of pituitary volume with magnetic resonance imaging and systematic stereology: Relationship to dexamethasone suppression test results in patients. <i>Psychiatry Research</i> , 1992, 44, 63-70.	1.7	120
567	CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia. <i>Psychiatry Research</i> , 1992, 43, 13-21.	1.7	15
568	Pharmacological specificity of the increase in neurotensin concentrations after antipsychotic drug treatment. <i>Brain Research</i> , 1992, 575, 325-328.	1.1	26
569	5 $\alpha$ -Pregnane-3 $\alpha$ ,21-diol-20-one (THDOC) attenuates mild stress-induced increases in plasma corticosterone via a non-glucocorticoid mechanism: comparison with alprazolam. <i>Brain Research</i> , 1992, 573, 353-355.	1.1	71
570	Cerebrospinal-Fluid Neuropeptides: A Biochemical Subgrouping Approach. <i>Neuropsychobiology</i> , 1992, 26, 37-42.	0.9	11
571	Calcium-, calcium/calmodulin-, and calcium/phospholipid-stimulated protein phosphorylation in the rat anterior pituitary. <i>Synapse</i> , 1992, 11, 140-145.	0.6	0
572	Alterations in regional brain neurotensin concentrations produced by atypical antipsychotic drugs. <i>Regulatory Peptides</i> , 1991, 32, 193-201.	1.9	33
573	The neurobiology of neurotensin: focus on neurotensin-dopamine interactions. <i>Regulatory Peptides</i> , 1991, 36, 153-164.	1.9	114
574	The electrophysiological actions of neurotensin in the central nervous system. <i>Life Sciences</i> , 1991, 49, 987-1002.	2.0	45
575	A magnetic resonance imaging study of putamen nuclei in major depression. <i>Psychiatry Research - Neuroimaging</i> , 1991, 40, 95-99.	0.9	224
576	Fast feedback regulation of acth by cortisol. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1991, 15, 523-529.	2.5	11

#	ARTICLE	IF	CITATIONS
577	Neurotensin-sensitive protein phosphorylation in the rodent caudate nucleus. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1991, 15, 83-89.	2.5	2
578	Neurotensin effects on calcium/calmodulin-dependent protein phosphorylation in rat neostriatal slices. <i>Brain Research</i> , 1991, 545, 343-346.	1.1	6
579	Platelet [3H]-imipramine binding and leukoencephalopathy in geriatric depression. <i>Biological Psychiatry</i> , 1991, 29, 665-670.	0.7	13
580	MRI of corpus callosum and septum pellucidum in depression. <i>Biological Psychiatry</i> , 1991, 29, 300-301.	0.7	32
581	5 Neuropeptides and neurotransmitters in Alzheimer's disease: focus on corticotrophin releasing factor. <i>Bailliere's Clinical Endocrinology and Metabolism</i> , 1991, 5, 59-77.	1.0	5
582	Subcortical hyperintensities on brain magnetic resonance imaging: A comparison between late age onset and early onset elderly depressed subjects. <i>Neurobiology of Aging</i> , 1991, 12, 245-247.	1.5	188
583	Neurotransmitters and Neuropeptides in Alzheimer's Disease. <i>Psychiatric Clinics of North America</i> , 1991, 14, 421-442.	0.7	20
584	Subcellular Distribution of Corticotropin-Releasing-Factor-Like Immunoreactivity in Rat Central Nervous System. <i>Neuroendocrinology</i> , 1991, 54, 36-41.	1.2	6
585	Recent Advances in the Neurochemical Pathology of Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1991, 640, 193-196.	1.8	5
586	Neurosciences and neuropsychiatry Editorial overview. <i>Current Opinion in Psychiatry</i> , 1991, 4, 79-80.	3.1	0
587	The Detection of Depression by Patient Self-Report in Women with Gynecologic Cancer. <i>International Journal of Psychiatry in Medicine</i> , 1991, 21, 17-27.	0.8	29
588	Muscimol injections into the median raphe nucleus increase serum ACTH and corticosterone concentrations via a nonserotonergic mechanism. <i>Pharmacology Biochemistry and Behavior</i> , 1991, 39, 765-768.	1.3	3
589	Occult subcortical magnetic resonance findings in elderly depressives. <i>International Journal of Geriatric Psychiatry</i> , 1991, 6, 213-216.	1.3	25
590	Effects of CI-943, a potential antipsychotic drug, and haloperidol on regional brain neurotensin concentrations. <i>Synapse</i> , 1991, 9, 225-230.	0.6	13
591	Neuropeptide Concentrations in the Cerebrospinal Fluid of Depressed Patients Treated with Electroconvulsive Therapy. <i>British Journal of Psychiatry</i> , 1991, 158, 59-63.	1.7	233
592	Caudate Hyperintensities in Elderly Depressed Patients With Neuroleptic-Induced Parkinsonism. <i>Topics in Geriatrics</i> , 1991, 4, 86-89.	0.9	19
593	Pituitary Size in Depression*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 256-259.	1.8	198
594	Role for Brain Corticotropin-Releasing Factor in the Weight-Reducing Effects of Chronic Fenfluramine Treatment in Rats*. <i>Endocrinology</i> , 1991, 128, 3237-3246.	1.4	37

#	ARTICLE	IF	CITATIONS
595	Subclinical Hypothyroidism: A Review of Neuropsychiatric Aspects. <i>International Journal of Psychiatry in Medicine</i> , 1990, 20, 193-208.	0.8	119
596	Neuropeptides and Alzheimer's Disease. <i>Journal of the American Geriatrics Society</i> , 1990, 38, 918-925.	1.3	29
597	Elevated Plasma Concentrations of $\beta$ -1-Acid Glycoprotein, a Putative Endogenous Inhibitor of the Tritiated Imipramine Binding Site, in Depressed Patients. <i>Archives of General Psychiatry</i> , 1990, 47, 337.	13.8	55
598	Evidence for a role for corticotropin-releasing factor in the pathogenesis of anxiety disorders and in the action of triazolobenzodiazepines. <i>Journal of Psychiatric Research</i> , 1990, 24, 90-91.	1.5	0
599	Cyclic AMP-dependent protein phosphorylation in the rat anterior pituitary. <i>Synapse</i> , 1990, 5, 241-246.	0.6	1
600	Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. <i>Journal of Neuroscience</i> , 1990, 10, 176-183.	1.7	380
601	Corticotropin-Releasing Factor Concentrations Exhibit an Apparent Diurnal Rhythm in Hypothalamic and Extrahypothalamic Brain Regions: Differential Sensitivity to Corticosterone. <i>Neuroendocrinology</i> , 1990, 52, 626-631.	1.2	47
602	Nocturnal and early morning secretion of ACTH and cortisol in humans. <i>Biological Psychiatry</i> , 1990, 28, 47-57.	0.7	20
603	Adrenocortical sensitivity to low-dose ACTH administration in depressed patients. <i>Biological Psychiatry</i> , 1990, 27, 930-933.	0.7	30
604	Cerebrospinal fluid thyrotropin-releasing hormone concentrations in alcoholics and normal controls. <i>Biological Psychiatry</i> , 1990, 28, 767-772.	0.7	13
605	Plasma dexamethasone concentrations and the dexamethasone suppression test. <i>Biological Psychiatry</i> , 1990, 27, 159-173.	0.7	51
606	Is decreased imipramine binding by platelet membranes in major depression associated with plasma autoantibodies to imipramine binding sites?. <i>Biological Psychiatry</i> , 1990, 28, 365-368.	0.7	4
607	Effects of sigma receptor blockade on regional brain neurotensin concentrations. <i>European Journal of Pharmacology</i> , 1990, 183, 2323-2324.	1.7	0
608	Effects of 5-HT <sub>1A</sub> receptor agonists on hypothalamo-pituitary-adrenal axis activity and corticotropin-releasing factor containing neurons in the rat brain. <i>European Journal of Pharmacology</i> , 1990, 190, 113-122.	1.7	60
609	In vivo stereological assessment of caudate volume in man: Effect of normal aging. <i>Life Sciences</i> , 1990, 47, 1325-1329.	2.0	72
610	Pharmacokinetics of growth hormone secretion in humans induced by growth hormone releasing hormone. <i>Life Sciences</i> , 1990, 47, 1887-1893.	2.0	3
611	The presence of antithyroid antibodies in patients with affective and nonaffective psychiatric disorders. <i>Biological Psychiatry</i> , 1990, 27, 51-60.	0.7	71
612	Cerebrospinal Fluid Concentrations of Neurotensin and Corticotropin-Releasing Factor in Pediatric Patients. <i>Neonatology</i> , 1989, 55, 260-267.	0.9	10

#	ARTICLE	IF	CITATIONS
613	A Critical Evaluation of Cysteamine as a Tool to Deplete Somatostatin in the Rat Central Nervous System*. <i>Endocrinology</i> , 1989, 124, 855-861.	1.4	18
614	Acute effects of alprazolam and adinazolam on the concentrations of corticotropin-releasing factor in the rat brain. <i>Synapse</i> , 1989, 4, 196-202.	0.6	86
615	Thyrotropin-Releasing Hormone (TRH), the Thyroid Axis, and Affective Disorder. <i>Annals of the New York Academy of Sciences</i> , 1989, 553, 304-310.	1.8	26
616	Behavioral effects of neurotensin: operant responding and assessment of "anhedonia". <i>European Journal of Pharmacology</i> , 1989, 163, 119-122.	1.7	5
617	Effects of anticholinergic drugs on regional brain neurotensin concentrations. <i>European Journal of Pharmacology</i> , 1989, 165, 327-330.	1.7	10
618	Effects of short- and long-term haloperidol administration and withdrawal on regional brain cholecystokinin and neurotensin concentrations in the rat. <i>Brain Research</i> , 1989, 480, 178-183.	1.1	43
619	Neuropeptides in Alzheimer's disease: a postmortem study. <i>Regulatory Peptides</i> , 1989, 25, 123-130.	1.9	52
620	The corticotropin-releasing hormone test in patients with posttraumatic stress disorder. <i>Biological Psychiatry</i> , 1989, 26, 349-355.	0.7	221
621	CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: Its relationship to severity of dementia and monoamine metabolites. <i>Biological Psychiatry</i> , 1989, 26, 500-504.	0.7	64
622	Neuroanatomical changes and hypothalamo-pituitary-adrenal axis abnormalities. <i>Biological Psychiatry</i> , 1989, 26, 729-732.	0.7	31
623	Elevated CSF CRF in suicide victims. <i>Biological Psychiatry</i> , 1989, 25, 355-359.	0.7	204
624	Reduced inhibitory effect of imipramine on radiolabeled serotonin uptake into platelets in geriatric depression. <i>Biological Psychiatry</i> , 1989, 25, 687-691.	0.7	20
625	Growth Hormone Response to Growth Hormone Releasing Factor in Alzheimer's Disease. <i>Neuroendocrinology</i> , 1989, 50, 663-666.	1.2	18
626	Differential effects of antipsychotic drugs on the neurotensin concentration of discrete rat brain nuclei. <i>Biochemical Pharmacology</i> , 1988, 37, 1547-1554.	2.0	99
627	One stressful event blocks multiple actions of diazepam for up to at least a month. <i>Brain Research</i> , 1988, 445, 380-385.	1.1	47
628	Neuropeptides, Dopamine, and Schizophrenia. <i>Annals of the New York Academy of Sciences</i> , 1988, 537, 273-291.	1.8	33
629	Neurotensin and the Mesocorticolimbic Dopamine System. <i>Annals of the New York Academy of Sciences</i> , 1988, 537, 397-404.	1.8	20
630	Neurotensin Stimulates the Phosphorylation of Caudate Nucleus Synaptosomal Proteins. <i>Annals of the New York Academy of Sciences</i> , 1988, 537, 488-490.	1.8	6

#	ARTICLE	IF	CITATIONS
631	Intra-Accinnbens Injection of Neurotensin Antagonizes the Behavioral Supersensitivity to L-DOPA in Dopamine-Denervated Rats. <i>Annals of the New York Academy of Sciences</i> , 1988, 537, 496-497.	1.8	0
632	Alterations in Neurotensin- and Bombesin-like Immunoreactivity in MPTP-Treated Mice. <i>Annals of the New York Academy of Sciences</i> , 1988, 537, 515-517.	1.8	2
633	Growth hormone response to growth hormone-releasing factor in depression. <i>Peptides</i> , 1988, 9, 113-116.	1.2	30
634	Elevated CSF dynorphin A [1â€“8] in Tourette's syndrome. <i>Life Sciences</i> , 1988, 43, 2015-2023.	2.0	61
635	Leukoencephalopathy in patients diagnosed as major depressive. <i>Biological Psychiatry</i> , 1988, 23, 519-522.	0.7	225
636	Adrenocortical sensitivity to ACTH in humans. <i>Biological Psychiatry</i> , 1988, 24, 105-108.	0.7	24
637	Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients. <i>Journal of Affective Disorders</i> , 1988, 14, 99-107.	2.0	71
638	The neurobiology of aging and the neurobiology of depression: Is there a relationship?. <i>Neurobiology of Aging</i> , 1988, 9, 120-122.	1.5	8
639	Interactions of neurotensin with dopamine-containing neurons in the central nervous system. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1988, 12, S53-S69.	2.5	30
640	Alterations in cerebrospinal fluid concentrations of somatostatin-like immunoreactivity in chronic pain patients. <i>Pain</i> , 1988, 33, 169-172.	2.0	8
641	Reduced Corticotropin Releasing Factor Binding Sites in the Frontal Cortex of Suicide Victims. <i>Archives of General Psychiatry</i> , 1988, 45, 577.	13.8	520
642	Marked Reduction in the Number of Plateletâ€“Tritiated Imipramine Binding Sites in Geriatric Depression. <i>Archives of General Psychiatry</i> , 1988, 45, 919.	13.8	93
643	Preclinical and Clinical Evidence for the Involvement of Corticotropin-Releasing Factor in the Pathogenesis of Depression. <i>Advances in Experimental Medicine and Biology</i> , 1988, 245, 479-487.	0.8	2
644	Chapter 22 The role of peptides in affective disorders: a review. <i>Progress in Brain Research</i> , 1987, 72, 235-247.	0.9	10
645	Neurotensin Alters Phosphorylation of Neostriatal Proteins. <i>Annals of the New York Academy of Sciences</i> , 1987, 494, 98-100.	1.8	2
646	Stress-induced alterations in neurotensin, somatostatin and corticotropin-releasing factor in mesotelencephalic dopamine system regions. <i>Brain Research</i> , 1987, 417, 350-354.	1.1	79
647	The clinical use of the dexamethasone suppression test in DSM-III affective disorders: Correlation with the severe depressive subtypes of melancholia and psychosis. <i>Journal of Psychiatric Research</i> , 1987, 21, 185-194.	1.5	60
648	The dexamethasone suppression test and antidepressant response in major depression. <i>Journal of Psychiatric Research</i> , 1987, 21, 313-317.	1.5	4

#	ARTICLE	IF	CITATIONS
649	Electroconvulsive therapy of depression in patients with white matter hyperintensity. <i>Biological Psychiatry</i> , 1987, 22, 629-636.	0.7	38
650	Use of the dexamethasone suppression test with DSM-III criteria in psychiatrically hospitalized adolescents. <i>Psychoneuroendocrinology</i> , 1987, 12, 203-209.	1.3	10
651	Centrally administered neurotensin inhibits pentobarbital metabolism in mice but not in rats. <i>Neuroscience Letters</i> , 1987, 77, 311-315.	1.0	4
652	The effects of thyroid state on beta-adrenergic and serotonergic receptors in rat brain. <i>Psychoneuroendocrinology</i> , 1987, 12, 261-270.	1.3	81
653	CSF monoamine metabolites in chronic pain. <i>Pain</i> , 1987, 31, 189-198.	2.0	14
654	A comparison of cocaine and its metabolite norcocaine: Effects on locomotor activity. <i>Pharmacology Biochemistry and Behavior</i> , 1987, 26, 573-575.	1.3	21
655	Evidence for a tonic facilitatory influence of substance P on dopamine release in the nucleus accumbens. <i>Brain Research</i> , 1986, 385, 379-382.	1.1	46
656	Hypothalamic-Pituitary-Adrenal Axis and Suicide. <i>Annals of the New York Academy of Sciences</i> , 1986, 487, 263-270.	1.8	59
657	The interaction of neurotensin with dopaminergic pathways in the central nervous system: Basic neurobiology and implications for the pathogenesis and treatment of schizophrenia. <i>Psychoneuroendocrinology</i> , 1986, 11, 15-37.	1.3	169
658	Repeated neurotensin administration in the ventral tegmental area: Effects on baseline and d-amphetamine-induced locomotor activity. <i>Neuroscience Letters</i> , 1986, 68, 239-244.	1.0	61
659	Behavioral effects of neurotensin in the open field: structure-activity studies. <i>Brain Research</i> , 1986, 381, 259-265.	1.1	35
660	Adaptation to cold antagonizes neurotensin-induced hypothermia in mice. <i>Brain Research</i> , 1986, 369, 136-142.	1.1	3
661	Chapter 9 Neuropeptides and schizophrenia. <i>Progress in Brain Research</i> , 1986, 66, 161-174.	0.9	10
662	Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. <i>Journal of Neuroscience</i> , 1986, 6, 2908-2914.	1.7	470
663	Dr. Nemeroff and Associates Reply. <i>American Journal of Psychiatry</i> , 1986, 143, 555-a-556.	4.0	0
664	Release of Corticotropin-Releasing Factor from Rat Brain Regions <i>In Vitro</i> *. <i>Endocrinology</i> , 1986, 118, 1997-2001.	1.4	65
665	Drs. Evans and Nemeroff Reply. <i>American Journal of Psychiatry</i> , 1985, 142, 992-992.	4.0	2
666	Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's disease. <i>Annals of Neurology</i> , 1985, 17, 324-328.	2.8	64

#	ARTICLE	IF	CITATIONS
667	Effects of Intrahypothalamic Injection of Quinolinic Acid on Anterior Pituitary Hormone Secretion in the Unanesthetized Rat. <i>Neuroendocrinology</i> , 1985, 41, 332-336.	1.2	8
668	Changes of CSF neuropeptides after environmental stimulation in dementia. <i>Nordic Journal of Psychiatry</i> , 1985, 39, 75-81.	0.2	24
669	Role of the autonomic nervous system in the cytoprotective effect of neurotensin against gastric stress ulcers in rats. <i>Psychoneuroendocrinology</i> , 1985, 10, 149-157.	1.3	26
670	Neuropeptides in CSF and post-mortem brain tissue of normal controls, schizophrenics and huntington's choreics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1985, 9, 97-108.	2.5	17
671	Introduction. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1985, 9, 53-54.	2.5	0
672	Microinjection of neurotensin into the ventral tegmental area produces hypothermia: Evaluation of dopaminergic mediation. <i>Brain Research</i> , 1985, 326, 219-227.	1.1	28
673	Bombesin-like immunoreactivity in the central nervous system of capsaicin-treated rats: a radioimmunoassay and immunohistochemical study. <i>Brain Research</i> , 1985, 342, 1-8.	1.1	36
674	Neurotensin-dopamine interactions in the CNS. <i>Trends in Pharmacological Sciences</i> , 1985, 6, 201-205.	4.0	123
675	Neonatal treatment with monosodium glutamate does not alter grooming behavior induced by novelty or adrenocorticotrophic hormone. <i>Behavioral and Neural Biology</i> , 1985, 44, 80-89.	2.3	10
676	Effects of neonatal treatment with 6-aminonicotinamide on basal and isoproterenol-stimulated ornithine decarboxylase activity in cerebellum of the developing rat. <i>Biochemical Pharmacology</i> , 1985, 34, 3281-3284.	2.0	11
677	Ontogeny of Brain Neurotensin in the Rat: A Radioimmunoassay Study. <i>Journal of Neurochemistry</i> , 1984, 43, 283-287.	2.1	47
678	Prevention of stress-induced gastric ulcers by dopamine agonists in the rat. <i>Life Sciences</i> , 1984, 35, 2453-2458.	2.0	75
679	Behavioral effects of hypothalamic hypophysiotropic hormones, neurotensin, substance P and other neuropeptides. , 1984, 24, 1-56.		62
680	Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. <i>Neuroscience</i> , 1984, 11, 919-930.	1.1	149
681	Bombesin-induced locomotor hyperactivity: evaluation of the involvement of the mesolimbic dopamine system. <i>Brain Research</i> , 1984, 304, 377-382.	1.1	38
682	Evidence for biological activity of two N-terminal fragments of neurotensin, neurotensin $\epsilon$ 8 and neurotensin $\epsilon$ 10. <i>Brain Research</i> , 1984, 301, 153-156.	1.1	21
683	Monosodium glutamate lesions in rat hypothalamus studied by immunohistochemistry for gonadotropin releasing hormone, neurotensin, tyrosine hydroxylase, and glutamic acid decarboxylase and by autoradiography for [3H]estradiol. <i>Brain Research</i> , 1984, 308, 245-253.	1.1	32
684	Neurotensin-induced antinociception and hypothermia in mice: antagonism by TRH and structural analogs of TRH. <i>Regulatory Peptides</i> , 1984, 8, 41-49.	1.9	19

#	ARTICLE	IF	CITATIONS
685	Drs. Evans and Nemeroff Reply. <i>American Journal of Psychiatry</i> , 1984, 141, 146-a-147.	4.0	1
686	Peptides and Nociception. <i>International Review of Neurobiology</i> , 1984, 25, 185-241.	0.9	34
687	The effects of neurotensin, $\hat{\mu}^2$ -endorphin and bombesin on ethanol-induced behaviors in mice. <i>Psychopharmacology</i> , 1983, 79, 357-363.	1.5	22
688	The effects of chronic morphine treatment on neurotensin-induced antinociception. <i>Psychopharmacology</i> , 1983, 81, 10-13.	1.5	15
689	The effect of centrally administered neuropeptides on the development of stress-induced gastric ulcers in rats. <i>Journal of Neuroscience Research</i> , 1983, 9, 145-157.	1.3	76
690	Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. <i>Neuroscience</i> , 1983, 8, 495-505.	1.1	201
691	Effect of prostaglandin synthesis inhibitors on neurotensin and sodium salicylate-induced gastric cytoprotection in rats. <i>Life Sciences</i> , 1983, 32, 2905-2910.	2.0	16
692	Intracameral administration of neurotensin induces miosis in the rabbit. <i>Neuropeptides</i> , 1983, 4, 31-40.	0.9	15
693	Increase in plasma $\hat{\mu}^2$ -endorphin-like immunoreactivity at parturition in normal women. <i>American Journal of Obstetrics and Gynecology</i> , 1983, 145, 111-113.	0.7	15
694	The anhedonia hypothesis of neuroleptic drug action: Basic and clinical considerations. <i>Behavioral and Brain Sciences</i> , 1982, 5, 70-71.	0.4	12
695	Ontogeny of the hypothermic response to centrally administered neurotensin in rats. <i>Developmental Brain Research</i> , 1982, 3, 497-501.	2.1	20
696	Antinociception after microinjection of neurotensin into the central amygdaloid nucleus of the rat. <i>Brain Research</i> , 1982, 243, 279-286.	1.1	88
697	The effects of neuropeptides on discrete-trial conditioned avoidance responding. <i>Brain Research</i> , 1982, 237, 183-192.	1.1	53
698	The effect of neurotensin on food consumption in the rat. <i>European Journal of Pharmacology</i> , 1982, 81, 499-503.	1.7	107
699	The effect of intracisternally administered bombesin on cysteamine-induced duodenal ulcers in rats. <i>European Journal of Pharmacology</i> , 1982, 84, 205-209.	1.7	23
700	Neuroanatomical site specific modulation of spontaneous motor activity by neurotensin. <i>European Journal of Pharmacology</i> , 1982, 78, 471-474.	1.7	71
701	NEUROANATOMICAL SITES OF ACTION OF NEUROTENSIN. <i>Annals of the New York Academy of Sciences</i> , 1982, 400, 307-318.	1.8	34
702	INTERACTIONS OF NEUROTENSIN WITH BRAIN DOPAMINE SYSTEMS. <i>Annals of the New York Academy of Sciences</i> , 1982, 400, 330-344.	1.8	80



#	ARTICLE	IF	CITATIONS
703	THE MANIFOLD ACTIONS OF NEUROTENSIN: A FIRST SYNTHESIS. <i>Annals of the New York Academy of Sciences</i> , 1982, 400, 368-376.	1.8	30
704	TOPOGRAPHY AND FUNCTIONAL IMPLICATIONS OF NEUROTENSIN-CONTAINING STRUCTURES IN THE RAT BRAIN. <i>Annals of the New York Academy of Sciences</i> , 1982, 400, 403-404.	1.8	1
705	Interaction of neurotensin with prostaglandin E2 and prostaglandin synthesis inhibitors: effects on colonic temperature in mice. <i>Regulatory Peptides</i> , 1982, 4, 285-292.	1.9	13
706	Neurotensin: Topographical distribution of brain sites involved in hypothermia and antinociception. <i>Journal of Comparative Neurology</i> , 1982, 210, 225-238.	0.9	103
707	Regional Distribution of Neurotensin in Human Brain. <i>Journal of Neurochemistry</i> , 1982, 38, 1777-1780.	2.1	113
708	Thyrotropin-releasing hormone and amphetamine produce different patterns of behavioral excitation in rats. <i>European Journal of Pharmacology</i> , 1981, 72, 35-43.	1.7	49
709	Increase in spontaneous motor activity following infusion of neurotensin into the ventral tegmental area. <i>Brain Research</i> , 1981, 229, 525-529.	1.1	106
710	Modification of the actions of ethanol by centrally active peptides. <i>Peptides</i> , 1981, 2, 99-106.	1.2	47
711	Marked Reduction in Gonadal Steroid Hormone Levels in Rats Treated Neonatally with Monosodium L-Glutamate: Further Evidence for Disruption of Hypothalamic-Pituitary-Gonadal Axis Regulation. <i>Neuroendocrinology</i> , 1981, 33, 265-267.	1.2	58
712	Neurotensin blocks certain amphetamine-induced behaviours. <i>Nature</i> , 1981, 291, 73-76.	13.7	218
713	Effect of Chronic Treatment with Thyrotropin-Releasing Hormone (TRH) or an Analog of TRH (Linear) Tj ETQq1 1 0.784314 rgBT /Over	1.2	30
714	Lack of effect of a behaviorally active dose of cholecystokinin octapeptide upon aromatic amino acid levels in plasma and brain. <i>Brain Research</i> , 1980, 184, 529-532.	1.1	1
715	Neurotensin-induced hypothermia: Evidence for an interaction with dopaminergic systems and the hypothalamic-pituitary-thyroids axis. <i>Brain Research</i> , 1980, 195, 69-84.	1.1	136
716	Neurotensin and bombesin: differential effects on body temperature of mice after intracisternal administration. <i>Regulatory Peptides</i> , 1980, 1, 53-60.	1.9	40
717	Neurotensin: central nervous system effects of a neuropeptide. <i>Trends in Neurosciences</i> , 1980, 3, 212-215.	4.2	90
718	Effects of intracisternal neurotensin, $\hat{1}^2$ -endorphin or bombesin on ethanol-induced sedation and hypothermia. <i>Drug and Alcohol Dependence</i> , 1980, 6, 112-113.	1.6	4
719	Neurotensin: Distribution of hypothermic response in mammalian and submammalian vertebrates. <i>Pharmacology Biochemistry and Behavior</i> , 1979, 11, 473-477.	1.3	35
720	Centrally administered neurotensin: Activity in the Julou-Courvoisier muscle relaxation test in mice. <i>European Journal of Pharmacology</i> , 1979, 54, 299-302.	1.7	67

#	ARTICLE	IF	CITATIONS
721	Thyrotropin-releasing hormone and amphetamine: A comparison of pharmacological profiles in animals. <i>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</i> , 1979, 3, 303-314.	0.6	22
722	Experimental studies on the ultrastructural localization of acetylcholinesterase in the mediobasal hypothalamus of the rat. <i>Journal of Comparative Neurology</i> , 1978, 182, 201-219.	0.9	9
723	Neurotensin, a biologically active peptide. <i>Life Sciences</i> , 1978, 23, 2173-2182.	2.0	80
724	Effects of acute administration of monosodium-L-glutamate (MSG), atropine or haloperidol on anterior pituitary hormone secretion in the rat. <i>Brain Research</i> , 1978, 156, 198-201.	1.1	25
725	Reduced hypothalamic content of immunoreactive LH-RH-like activity in genetically obese/ob mice. <i>Brain Research</i> , 1978, 146, 385-387.	1.1	17
726	Direct Evidence that the Arcuate Nucleus-Median Eminence Tuberoinfundibular System Is Not of Primary Importance in the Feedback Regulation of Luteinizing Hormone and Follicle-Stimulating Hormone Secretion in the Castrated Rat*. <i>Endocrinology</i> , 1978, 103, 170-175.	1.4	42
727	Models of Neuroendocrine Regulation: Use of Monosodium Glutamate as an Investigational Tool. <i>Developmental Neuroscience</i> , 1978, 1, 102-109.	1.0	66
728	Peptides and Psychoneuroendocrinology. <i>Archives of General Psychiatry</i> , 1978, 35, 999.	13.8	45
729	Analysis of the Disruption in Hypothalamic-Pituitary Regulation in Rats Treated Neonatally with Monosodium L-Glutamate (MSG): Evidence for the Involvement of Tuberoinfundibular Cholinergic and Dopaminergic Systems in Neuroendocrine Regulation. <i>Endocrinology</i> , 1977, 101, 613-622.	1.4	193
730	Growth, endocrinological and behavioral deficits after monosodium L-glutamate in the neonatal rat: possible involvement of arcuate dopamine neuron damage. <i>Psychoneuroendocrinology</i> , 1977, 2, 179-196.	1.3	102
731	The role of hormones in depression. <i>Life Sciences</i> , 1977, 20, 1305-1317.	2.0	53
732	Neurotensin: Central nervous system effects of a hypothalamic peptide. <i>Brain Research</i> , 1977, 128, 485-496.	1.1	253
733	Biochemical and histochemical evidence for the existence of a tuberoinfundibular cholinergic pathway in the rat. <i>Brain Research</i> , 1977, 129, 169-173.	1.1	55
734	Lack of effect of chronically administered thyrotropin-releasing hormone (TRH) on regional rat brain tyrosine hydroxylase activity. <i>Pharmacology Biochemistry and Behavior</i> , 1977, 6, 467-469.	1.3	9
735	Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. <i>Nature</i> , 1976, 262, 607-609.	13.7	300
736	Comparison of the analeptic potency of TRH, ACTH 4-10, LHRH, and related peptides. <i>Pharmacology Biochemistry and Behavior</i> , 1976, 5, 135-138.	1.3	32
737	Lack of protection by pyridoxine or hydrazine pretreatment against monosodium L-glutamate-induced seizures. <i>Pharmacology Biochemistry and Behavior</i> , 1975, 3, 927-929.	1.3	7
738	Modification of pentobarbital effects by natural and synthetic polypeptides: Dissociation of brain and pituitary effects. <i>Life Sciences</i> , 1975, 16, 1907-1913.	2.0	67

#	ARTICLE	IF	CITATIONS
739	Neuroendocrinological Research in Psychiatry. , 0, , 91-124.		0
740	Neuroendocrinology. , 0, , 97-110.		0
741	Trauma and Depression. , 0, , 360-381.		3
742	The neuroendocrine effects of early life trauma. , 0, , 157-165.		2
743	Pharmacological treatment of bipolar depression. , 0, , 24-32.		0